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The maintenance of normal blood gas values is of major importance in the perioperative 
setting. Both anesthetics and analgesics (particularly opioids) may affect the ability of the 
human body to respond adequately to possible life-threatening decreases in oxygen tension 
(PO2) and rises in carbon dioxide tension (PCO2) in arterial blood.1-3 In the control system 
regulating pulmonary ventilation, the peripheral chemoreceptors, located within the carotid 
bodies, and central chemoreceptors in the brain stem play a crucial role in correcting the 
arterial PO2 and PCO2 once they are compromised by depressant effects of pharmacological 
agents that are used in anesthetic practice before, during and after a surgical procedure.1-3   
 
In extreme cases, for example in patients suffering from obstructive and/or central 
postoperative sleep apnea (often related to underlying disease such as the obstructive sleep 
apnea syndrome, the residual effects of anesthetics and the relative overdosing of opioid 
analgesics for postoperative pain relief), the availability of agents that are able to reverse 
severe respiratory depression is of life-saving importance. In the past decades, several studies 
in our laboratory have addressed the ability to reverse the respiratory depressant effects of 
opioids and anesthetics in animal and human studies.4,5 An example of an agent that reverses 
the adverse effects of opioids on breathing is the opioid receptor antagonist naloxone. 
Naloxone is closely related to morphine (figure 1) and antagonizes the following three opioid 
receptors: µ-, κ- and δ-opioid receptors. Naloxone is able to reverse respiratory depression 
from commonly used perioperative opioids, such as morphine and fentanyl, at relative low 
intravenous doses ranging from 100 to 400 µg (dose for a 70–80 kg person).6 Note, however, 
that with the disappearance of the opioid-induced side effect, also the intended effect (pain 
relief) is severely affected (i.e., reduced) by naloxone.  
 
 
Buprenorphine: respiratory behavior and reversal with naloxone 
 
Surprisingly little is known about the ability of naloxone to reverse respiratory depression 
from one specific opioid, buprenorphine. Buprenorphine is a potent opioid analgesic used in 
the treatment of chronic and acute pain and used in the treatment of heroin addiction. The use 
of buprenorphine has gained in popularity due to the recent introduction of buprenorphine 
matrix patches for the treatment of chronic (malignant and non-malignant) pain and 
replacement of methadone by buprenorphine in the treatment of heroin addiction. It has 
several special and unique properties.7 Buprenorphine is a semisynthetic opioid derived from 
thebaine, an alkaloid present in the poppy Papaver somniferum. The chemical structure of 
Chapter 1 
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Box 1: Physiology of the Control of Breathing 
 
Breathing is the process in which air flows into (inspiration) and out of (expiration) the 
lungs. The lungs expand during inspiration due to contraction of the diaphragm and external 
intercostal muscles. Expiration is passive (at least during rest). Skeletal muscles of the 
mouth and pharynx (incl. tongue and glottis) and smooth muscles of the airways play an 
important role in flow formation due to their role in modulation of airway resistance.  
 
Breathing results from rhythmic activity of the respiratory centers in the brain stem. Recent 
studies suggest the existence of two separate but coupled brainstem respiratory oscillators.28 
The dominant one, the preBötzinger complex (preBötC), contains µ-opioid receptors and is 
one of the sites involved in opioid-induced respiratory depression.29 The other respiratory 
center is the retrotrapezoid nucleus (RTN). The preBötC and RTN are part of the ventral 
respiratory column. 
 
Breathing is well adjusted to the metabolic and non-metabolic needs of the body. The 
respiratory centers themselves cannot account for adjustment of breathing in response to 
changes in metabolic requirements. They receive input from various sites in the body 
(hypothalamus, lung receptors, proprioreceptors in muscles and joints, peripheral and 
central chemoreceptors, cortex, subcortical regions) and send neuronal signals to the 
respiratory muscles. With respect to the chemical control of breathing, the chemical 
composition of arterial blood primarily regulates breathing through their effect on the 
peripheral and central chemoreceptors.1,2 The peripheral chemoreceptors in the carotid 
bodies are sensitive to changes in arterial pH, PCO2 and pO2.  The central chemoreceptors 
on the surface of the ventral medulla are sensitive to changes in brain tissue PCO2 and pH. 
To maintain a chemical equilibrium in the body, the metabolic control system makes use of 
two reflex arcs. The peripheral chemoreflex loop consists of the peripheral chemoreceptors, 
the sinus nerve, sites in the brainstem that receive and process afferent input from the 
carotid bodies, the brainstem respiratory centers and the neuromechanical link between 
brainstem and ventilation (phrenic nerve, spinal motoneurons, diaphragm, intercostal nerves 
and muscles, lungs). The central chemoreflex loop involves the central chemoreceptors, and 
neuronal connections between these receptors and the brainstem respiratory centers and the 
above-mentioned link between respiratory centers and ventilation. Animal studies showed 
the presence of opioid receptors in the carotid bodies.30 
 
Pure chemical control of breathing operates during non rapid-eye-movement (REM) sleep 
and during anesthesia (at least in spontaneous breathing patients). During wakefulness and 
REM-sleep another equally important system, the behavioral control system, will influence 
breathing and may even temporarily override the chemical system. Behavioral control of 
breathing allows for the adjustment of breathing to voluntary efforts such as speech, 
singing, eating, diving, et cetera. Pain may both stimulate and depress breathing. These 
effects are chemoreflex- and arousal-state-independent.  
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buprenorphine contains the general morphine skeleton (figure 1). In contrast to morphine, 
buprenorphine is considered a partial agonist for the µ-opioid receptor. This indicates that 
despite full receptor occupancy it shows a partial or limited effect. Some animal studies show 
ceiling (the occurrence of an apparent maximum in effect), a bell-shaped dose-response curve 
(or inverse U-shaped response curve) with respect to buprenorphine’s antinociceptive and 
respiratory depressant effects (see also figure 2).8-10  In this respect, no human data is 
available. Furthermore, buprenorphine displays high µ-opioid receptor affinity (K-values in 
the subnanomolar range) with slow receptor association/dissociation kinetics.7,11 In humans, 
buprenorphine’s µ-opioid receptor affinity is so high that reversal of buprenorphine’s adverse 
effects is impossible with low doses of naloxone (up to 400 µg). And even with high naloxone 




          
 




The first objective of this thesis is to describe the behavior of buprenorphine in humans with 
respect to its most important unwanted side effect, respiratory depression (chapter 2), and 
compare this with its intended effect, analgesia (chapter 3). The studies were designed to 
enable us to answer the question whether buprenorphine shows ceiling in its respiratory 
and/or analgesic behavior. Next, we studied the ability of naloxone to reverse buprenorphine-
induced respiratory depression in an extensive set of experiments. The ability of naloxone to 
reverse buprenorphine-induced respiratory depression was tested in a dose range from 0.5 to 
7 mg per 70 kg (using a continuous naloxone infusion rather than bolus infusions) and 
compared to naloxone’s ability to reverse morphine- and alfentanil-induced respiratory 
depression (chapter 4). 
Chapter 1 
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Box 2: The Opioid System and Pain Inhibition 
 
The opioid system is composed of a family of structurally related endogenous peptides that 
act at three receptor types known as µ-, κ- and δ-opioid receptors.31 Recently, a fourth 
receptor has been discovered with a strong homology with the three classical opioid 
receptors. Because of its likeness with these receptors the new receptor was named ORL1 or 
opioid receptor-like type 1.32 The opioid system is involved in responses to pain, stress and 
emotion and has a modulatory influence on various physiological functions such as the 
control of breathing, thermoregulation, appetite, nociception and the immune response.31 
Various endogenous opioid peptides have been discovered (for example, β-endorphin, 
enkephalin, dynorphin, endomorphin, nociceptin/orphanin FQ) but there is still much 
discussion about their exact function and distribution within the central nervous system. 
 
The opioid receptor is a seven-transmembrane G-protein-coupled receptor. Activation of the 
receptor will cause inhibition of neuronal activity due to:33  
(i) Inhibition of adenylate cyclase causing a decrease in cAMP,  
(ii) Opening of potassium channels (causing hyperpolarization of postsynaptic cells),  
(iii) Closure of calcium channels (causing a presynaptic decrease in neurotransmitter   
–such as substance P and glutamate– release).  
The G-proteins play a crucial role in these processes.  
 
The majority of opioid receptors (70% µ-opioid receptors, 25% δ-opioid receptors) come to 
expression on the membranes of neurones in the lamina I and substantia gelatinosa of the 
spinal cord. Activation of the opioid system for pain relief (from endogenous and 
exogenous opioids) is due to:33 
(i) Inhibition of neurones involved in pain perception (in afferent pathways in the 
spinal cord and supraspinal in pons and thalamus) and activation of descending 
pain inhibition pathways (locus coeruleus, raphe nuclei), 
(ii) Inhibition of pain perception, pain realization and central modulation of pain 
(supraspinal in thalamus and cortex),  
(iii) Suppression of the emotional component of pain (limbic system),  
(iv) Reduction of the level of arousal and autonomic responses to pain (reticular 
formation and locus coeruleus), 
(v) Furthermore, in case of inflammation at peripheral sites (for example, in case of 
arthritis), opioid receptors are expressed in the inflamed tissue and endogenous 
opioids are released from activated leucocytes.  
 
Typical µ-opioid side effects include: nausea, vomiting, respiratory depression, miosis, itch, 
inhibition of gastric motility, euphoria/dysphoria, hallucinations, sedation, muscle rigidity, 
cardiovascular depression, excitation, tolerance and addiction. Furthermore, recent findings 
indicate that opioids, aside from producing analgesia, display hyperalgesic behavior in 






















Figure 2. Buprenorphine dose-effect curve for antinociception 
in rats (electrical stimulation was used to assess 






Figure 3. Examples from one subject of the influence of an antioxidant cocktail (ascorbic acid plus 
α-tocopherol) on depression of the ventilatory response to acute hypoxia by low-dose isoflurane.  
A. Isoflurane causes > 50% depression of the ventilatory response to hypoxia; full reversal of effect is 
observed after pre-treatment with antioxidants. B. Isoflurane causes > 50% depression of the ventilatory 
response to hypoxia; no effect is seen after pre-treatment with placebo (NaCl 0.9%). C. No effect is 
observed after sham-isoflurane or antioxidants plus sham-isoflurane on the ventilatory response to acute 
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Figure 4. Chemical structures of acetazolamide (left) and methazolamide (right). 
 
 
Antioxidant-reversal of respiratory effects of drugs 
 
A major challenge in anesthesiology is to treat (i.e., reverse) respiratory depression due to 
opioids without affecting pain relief. A more detailed knowledge about the mechanisms by 
which the peripheral and central chemoreceptors operate is a prerequisite to bring this 
important clinical aim closer to reality. Therefore, a second focus of our studies in the past 
decades was put on the mechanism of the hypoxic and hypercapnic ventilatory responses.14,15  
One important finding was the ability of antioxidants (we used a combination of oral 
α-tocopherol –vitamin E– and intravenous ascorbic acid –vitamin C) to completely reverse the 
depression of the acute hypoxic ventilatory response (AHR) by subanesthetic concentrations 
of halothane and isoflurane (see also figure 3).5,16 Data from the literature strongly suggest 
that the AHR is mediated by the carotid bodies.17 The stimulus-response cascade in the 
carotid bodies is not completely known but studies in the last two decades have shown that 
the hypoxic response may be initiated by (various classes of) potassium channels that upon 
closure by hypoxia are responsible for depolarization of oxygen-sensitive cells. This 
depolarization is followed by influx of Ca2+ ions and release of neurotransmitters (presumably 
acetylcholine and ATP) that depolarize nearby nerve-endings of the glossopharyngeal nerve.18 
Potassium channels are also sensitive to (i.e., are opened by) halogenated volatile anesthetics. 
Interestingly, most potassium channels are also sensitive to reducing and oxidizing agents,19,20 
and this may explain the ability of antioxidants to reverse the inhibiting effects of halothane 
and isoflurane. These previous experiments raised the question whether the ability of 
antioxidants to reverse an inhibiting effect on the carotid bodies would also apply to inhibiting 
effects caused by other agents than anesthetics and thus might reflect a more general property 
of the carotid bodies when they are in a state of inhibition. Another pharmacological means to 
inhibit the carotid bodies is the carbonic anhydrase inhibitor acetazolamide (figure 4). In large 
intravenous doses, this agent completely abolishes the steady-state hypoxic response in 
animals,19,21 but literature data indicate that already clinical oral doses have an inhibiting 
effect on the carotid bodies.20,22 One question that we wished to answer in this thesis is 
whether antioxidants (the same mixture as described above) would also be able to reverse an 
inhibiting effect of a low intravenous dose of acetazolamide on the ventilatory response to 
acute isocapnic hypoxia in man (chapter 5). 
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The aforementioned inhibition of the AHR by acetazolamide is thought to result from 
inhibition of carbonic anhydrase that has been shown to be present in the carotid bodies.21,23 
However, methazolamide, a more lipid soluble carbonic anhydrase with similar affinity for 
carbonic anhydrase II and IV (the two major carbonic anhydrase isoforms that are blocked by 
acetazolamide and methazolamide), does not seem to affect the hypoxic response of an in 
vitro carotid body preparation,21,24 and this raises the question as to whether inhibition of 
carbonic anhydrase by acetazolamide is the underlying mechanism of its inhibiting effect on 
the hypoxic response indeed. Furthermore, recent studies have shown that acetazolamide has 
a specific opening effect on large conductance voltage-sensitive potassium (BK) channels, 
and possibly also on calcium- and sodium channels.22,25-27 These differences in physiological 
and pharmacological actions of acetazolamide and methazolamide raised the idea of 
comparing the effects of both agents on the steady-state hypercapnic and hypoxic response in 
the cat (chapters 6 and 7). The major question that we wished to answer was whether full 
activity of carbonic anhydrase is a necessary condition for an intact hypoxic response to 
occur, and whether the profound inhibiting effects of acetazolamide can be ascribed to 
inhibition of this enzyme or rather to another pharmacological action. 
 
 
The specific aims of this thesis are 
 
1. To describe the dose-respiratory response relationship of the opioid analgesic 
buprenorphine and compare this to the opioid fentanyl (chapter 2). Experiments were 
performed in healthy young volunteers. Respiration was measured using the computer-
controlled ‘dynamic end-tidal forcing technique’. 
 
2. To compare the respiratory and analgesic behavior of buprenorphine in healthy volunteers 
(chapter 3). 
 
3. To assess the ability of the opioid-antagonist naloxone to reverse buprenorphine-induced 
respiratory depression in humans (chapter 4). Studies focused on continuous infusions 
and doses. The buprenorphine data were compared to naloxone-reversal of morphine- and 
alfentanil-induced respiratory depression. 
 
4. To assess the ability of antioxidants to reverse acetazolamide-induced depression of the 
ventilatory response to acute hypoxia in humans (chapter 5).  
 
5. To describe and compare the effects of the carbonic anhydrase inhibitors acetazolamide 
and methazolamide on the ventilatory CO2 sensitivity and the hypoxic ventilatory 
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Ceiling and Naloxone-Reversal of Buprenorphine-







2 Comparison of the Respiratory Effects of Intravenous 
Buprenorphine and Fentanyl in Humans and Rats 
 
 
Buprenorphine is a semi-synthetic opioid analgesic used in clinical practice since 1979.1 In 
patients, buprenorphine is used for treatment of acute and chronic pain using various 
administration modes, such as intravenous, sublingual and spinal/epidural administration. 
Recently, interest in buprenorphine has been renewed due to the introduction of a new 
transdermal formulation for treatment of chronic malignant pain and due to the use of 
buprenorphine in the treatment of heroin addiction.1-3 Buprenorphine is a potent analgesic 
with agonistic activity at the µ-opioid receptor and the opioid receptor-like 1 (ORL1) receptor, 
and antagonistic properties at the κ-opioid receptor.4,5 In humans, buprenorphine behaves as a 
typical µ-opioid receptor agonist showing analgesia, sedation, nausea, delayed gastric 
emptying and respiratory depression.4,6 Animal studies suggest that buprenorphine, in contrast 
to other opioids, shows ceiling in its µ-agonist behavior such as analgesia and respiratory 
depression.4,7-9 Ceiling is best defined as an apparent maximum effect regardless of drug dose. 
The occurrence of ceiling is an important observation that is poorly studied in humans. 
Ceiling in respiratory effect has evident clinical advantages as opioids that possess this 
property are considered to be safer, because in theory they can not cause excessive respiratory 
depression.  
 
In this study we wished to assess whether there exists an apparent maximum in opioid-
induced respiratory depression for buprenorphine. We measured the respiratory responses to 
buprenorphine and compared them to fentanyl, a µ-opioid receptor agonist for which no 
ceiling has been observed.10 We performed experiments in two species, humans and rats, and 
obtained dose-response relationships using double-blind, placebo-controlled randomized 
designs. We studied both human and animal subjects, allowing us to expand the dose range 
beyond the rather limited dose range that is acceptable in awake humans. The dose range for 






Forty-eight volunteers (24 men, 24 women) participated in the protocol after approval was 
obtained from the local Human Ethics Committee. All subjects were healthy and did not have 
a history of illicit substance abuse. They were asked to refrain from stimulants and depressant 
substances for at least 12 h before the study. Each subject participated once. 
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Respiration. To study ventilation we used the dynamic end-tidal forcing technique.11 This 
technique enables us to force end-tidal PCO2 (PETCO2) and end-tidal PO2 (PETO2) to follow a 
specific pattern in time. In this study we clamped the PETCO2 and PETO2 to 7 kPa and 
14.5 kPa, respectively, throughout the studies. The subjects were comfortably positioned in a 
hospital bed and breathed through a face mask (Vital Signs, Totowa, NJ, USA), positioned 
over nose and mouth (a nose clip was not used). The face mask received fresh gas (45 l.min-1) 
from a gas mixing system consisting of three mass flow controllers (F202, Bronkhorst High-
Tech BV, Veenendaal, The Netherlands) for the delivery of oxygen, carbon dioxide and 
nitrogen. A personal computer running ACQ software (Erik Kruyt, Leiden University 
Medical Center, Leiden, The Netherlands) provided control signals to the mass flow 
controllers allowing the adjustment of the inspired gas concentrations to obtain the desired 
end-tidal concentrations. The in- and expired gas flows were measured at the mouth using a 
pneumotachograph connected to a pressure transducer (Hans Rudolph, Wyandotte, MI, USA) 
and electronically integrated to yield a volume signal. The volume signal was calibrated with 
a motor-driven piston pump. The oxygen and carbon dioxide concentrations were measured 
using a gas monitor (Multicap, Datex, Helsinki, Finland); a pulse oximeter (Masimo, Irvine, 
CA, USA) continuously measured the oxygen saturation (SpO2) of arterial hemoglobin with a 
finger probe. All relevant variables (minute ventilation, SpO2, PETCO2 and PETO2) were 
available for on-line analysis (using RRDP software, Erik Olofsen, Leiden University 
Medical Center, Leiden, The Netherlands) and stored on a breath-to-breath basis for further 
analysis. The bispectral index (BIS) of the EEG was monitored with a BIS XP machine 
(Aspect Medical Systems Inc., Newton, MA, USA; release 2002) using a four leads electrode 
placed on the forehead as specified by the manufacturer. BIS values were collected at 1-min 
intervals. 
 
The study was double-blind, randomized and placebo controlled. Prior to testing all subjects 
received 4 mg ondansetron i.v. (GlaxoSmithKline BV, Zeist, The Netherlands). The subjects 
were randomly assigned to receive placebo (0.9% NaCl), buprenorphine (Reckitt Benckiser 
Healthcare Ltd, Hull, UK) or fentanyl (Janssen-Cilag BV, Tilburg, The Netherlands). The 
following doses were given, placebo: 9 ml (n = 7); buprenorphine in 9 ml saline: 0.7 µg.kg-1 
(n = 5), 1.4 µg.kg-1 (n = 5), 4.3 µg.kg-1 (n = 5) and 8.6 µg.kg-1 (n = 5); fentanyl in 9 ml saline: 
1.1 µg.kg-1 (n = 5), 2.1 µg.kg-1 (n = 5), 2.9 µg.kg-1 (n = 5), 4.3 µg.kg-1 (n = 5) and 7.1 µg.kg-1 
(n = 1). The highest fentanyl dose (7.1 µg.kg-1) was tested only once. After the first subject 
was dosed with this dose, the respiratory effects were so severe (apnea > 5 min and SpO2 drop 
below 70%) that the blinding of this experiment was broken and a decision was made to no 
longer infuse the highest fentanyl dose. The data of the single subject receiving 7.1 µg.kg-1 
were used in the analysis.  
 
The respiratory studies started after a period of acclimatization to the apparatus and 
ventilation (at a PETCO2 of 7 kPa) had reached a steady state. Next the drug was infused 
slowly over 90 s. Subsequently continuous respiratory measurements were obtained for 80 to 
90 min, followed by 5 to 10 min measurements at 30 min intervals (until 4 h after drug 
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infusion) and next at 60 min intervals. In case ventilation returned to baseline values (defined 
by at least 5 min at or above baseline) prior to the end of the measurement periods the study 
was ended. In case this did not happen or in case there was no systematic respiratory 
depressant effect, the study ended seven hours after drug infusion. 
 
Data Analysis. We performed a 1-min average on the ventilation data of individual subjects. 
From these data we calculated peak ventilatory depression, time to peak effect and time to end 
of effect (i.e., return to baseline). The dose–peak ventilatory depression data were analyzed 
using the following sigmoid Emax model (Hill equation): 
 
Effect(dose) = Emax – (Emax – Emin) • [(dose/ED50)γ / (1 + (dose/ED50)γ)] 
 
where dose is the drug dose applied, ED50 the estimated dose causing 50% effect, Emax and 
Emin the maximum and minimum of the sigmoid function, respectively, and γ a shape 
parameter. The model parameters were estimated using nonlinear regression analysis 
(NONMEM version V, level 1.1, a data analysis program for nonlinear mixed effects 
modeling). The likelihood ratio criterion was used to assess whether Emin differed 
significantly from 0 l.min-1. 
 
In order to get an impression of the average drug effect on respiration over the measurement 
time we assessed the area between the curves standardized by the length of the study.12 The 
involved curves are measured ventilation normalized by predrug baseline (which per 
definition equals 1; see also figure 1). An average drug effect of 40 indicates an average 40% 
respiratory depression over the measured time period (i.e., from time of drug infusion to time 
to end of effect or end of study if time to end of effect had not been reached within 420 min).  
 
The time to peak effect and average drug effect data were analyzed using a one-way analysis 
of variance (factor: dose), with post-hoc Bonferroni correction for multiple comparisons. The 
buprenorphine and fentanyl groups were analyzed separately. P-values < 0.05 were 




Male Wistar rats (weight 225–250 g, n = 63) were housed in groups before surgery and 
individually after surgery in plastic cages. The animals were housed under laboratory standard 
conditions at constant room temperature (21 ºC) and on a 12-h light/dark cycle (lights on at 
07:00 AM; lights off at 07:00 PM). Food (RMH-TM; Hope Farms BV, Woerden, The 
Netherlands) and acidified water were allowed ad libitum. The animals were handled and 
allowed for acclimation to the experimental environment for ten days prior to the start of the 























Figure 1. Calculation of the average drug effect. 1: baseline ventilation (per definition = 1), 
2: ventilation normalized by the baseline value, 3: the area between lines 1 and 2 equals the average 
drug effect, 4: the time to end of effect. The average drug effect is divided by the time to end of effect 
or 420 min if time to end of effect had not been reached within 420 min. 
 
 
Surgical Procedure. Surgery was carried out under anesthesia with medetomidine 
hydrochloride (0.1 mg.kg-1 i.m.; Pfizer BV, Capelle a/d IJssel, The Netherlands) and ketamine 
base (1 mg.kg-1 i.m.; Parke-Davis BV, Hoofddorp, The Netherlands). Two days before the 
experiment two indwelling cannulae were implanted, one in the left femoral artery and one in 
the right jugular vein. The cannula in the right jugular vein was used for administration of the 
opioid or vehicle while the cannula in the left femoral artery was used for collection of arterial 
blood samples. The cannulae were made from pyrogen-free, non-sterile polyethylene tubing. 
The cannulae were tunnelled subcutaneously and fixed at the back of the neck with a rubber 
ring. In order to prevent clotting and cannula obstruction the cannulae were filled with a 25% 
(w/v) polyvinylpyrrolidone solution (PVP; Brocacef NV, Maarssen, The Netherlands) in 
pyrogen-free physiological saline (B. Braun Melsungen AG, Melsungen, Germany) 
containing 20 IU.ml-1 heparin. 
 
Drugs and Dosages. Fentanyl was dissolved in saline; buprenorphine was dissolved in saline 
with aid of two drops of polysorbate 80 (Hospital Pharmacy, Leiden University Medical 
Center, Leiden, The Netherlands). Henceforth, the doses of buprenorphine and fentanyl are 
expressed as free base. Each animal was tested once. For buprenorphine the following 
dosages were tested: 0 (vehicle), 100, 300, 1000 and 3000 µg.kg-1. For fentanyl the dosages 
were: 0 (vehicle), 50, 68 and 90 µg.kg-1. Fentanyl and buprenorphine were infused i.v. over 
20 min via a constant-rate infusion using an infusion pump (BAS Bioanalytical Systems, Inc., 
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West Lafayette, IN, USA). Animals were randomly assigned to the treatment groups with 
seven animals in each treatment level.  
 
Measurement of arterial PCO2. Arterial blood samples were obtained at fixed times for 
measurement of arterial PCO2 (PaCO2) using a blood gas analyzer (278, Bayer BV, 
Mijdrecht, The Netherlands). For buprenorphine these times were: baseline (5 to 10 min prior 
to drug infusion), 0, 30, 60, 120, 270 and 390 min after the start of drug administration; and 
for fentanyl: baseline, 5, 10, 15 and 20 min after the start of drug administration. Each blood 
sample withdrawn was replaced by an equal volume of heparinized 0.9% saline (heparin 
20 IU.ml-1). The difference in sampling schedule is related to the difference in speed of onset 
of the two tested opioids, with immediate changes in PaCO2 observed after fentanyl but not 
after buprenorphine infusion. During the experiments body temperature was maintained at 
37.5 ºC by a CMA/150 Temperature Controller (BAS Bioanalytical Systems, Inc.)  
 
Statistical Analysis. The buprenorphine and fentanyl studies were analyzed separately. A 
one-way analysis of variance was performed to assess the effect of drug dose per time, with 
post-hoc Bonferroni correction for multiple comparisons. P-values < 0.05 were considered 






The average age of the subjects was 22 years (range 19–34 years). Mean weight and height of 
the subjects was 72 kg (range 53–93 kg) and 176 cm (range 160–192 cm), respectively.  
 
Placebo. Placebo had no systematic effect on ventilation over the 420-min measurement 
period. Predrug ventilation was 22.7 (6.1) l.min-1. The lowest ventilation after drug infusion 
was at 180 min: 19.6 (4.6) l.min-1. The mean average drug effect was -0.1 (0.1). 
 
Fentanyl and Buprenorphine Time Profiles. The individual ventilatory responses of the 
subjects are given in figures 2 and 3. For both drugs, predrug ventilation did not differ among 
the doses: fentanyl 24.1 (6.0) l.min-1, buprenorphine 24.5 (4.1) l.min-1. After fentanyl, four 
subjects developed a period of apnea shortly after the infusion, one after 2.9 µg.kg-1 (duration 
< 3 min, lowest SpO2 measured 92%), two after 4.3 µg.kg-1 (duration < 3 min, lowest SpO2 
measured 91% and 93%) and one after 7.1 µg.kg-1 (8 min). Time to fentanyl peak effect did 
not differ among the doses tested: 4.8 (2.2) min. None of the subjects receiving buprenorphine 
developed apnea. Time to buprenorphine peak effect was dose independent and averaged 





































































Figure 2. Individual human ventilatory responses after 1.1, 2.1, 2.9, 4.3 and 7.1 µg.kg-1 fentanyl infusions. 



























































Figure 3. Individual human ventilatory responses after 0.7, 1.4, 4.3 and 8.6 µg.kg-1 buprenorphine infusions. 
Ventilation is normalized relative to baseline values. Different symbols and lines depict different subjects. 
Fentanyl 
 2.9 µg.kg-1 
 4.3 µg.kg-1  7.1 µg.kg-1 
 2.1 µg.kg-1 
    0.7 µg.kg-1 
4.3 µg.kg-1    8.6 µg.kg-1 
Buprenorphine 
   1.4 µg.kg-1 
1.1 µg.kg-1 
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Peak Drug Effect and Average Drug Effect. The dose–peak effect relationships are given in 
figure 4. For fentanyl there was a steep dose–response relationship eventually reaching 
0 l.min-1 (apnea). The data fit yielded the following parameter values (median (SE)): Emax 
20.1 (2.9) l.min-1, ED50 1.5 (0.5) µg.kg-1 and γ 2.0 (1.4); Emin did not differ significantly from 
0 l.min-1. For buprenorphine the dose–peak effect relationship showed an initial steep 
decrease in ventilation which levelled off at doses > 2 µg.kg-1. The data fit yielded the 
following parameter values: Emax 20.0 (0.8) l.min-1, ED50 0.9 (0.1) µg.kg-1 and γ 3.0 (0.9); Emin 
differed significantly from 0 l.min-1 and was estimated at 9.1 (0.6) l.min-1. The Emin value 
indicates that at a background PETCO2 of 7 kPa, the lowest value of minute ventilation after 
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Figure 4. Dose–response relationships for fentanyl (left) and buprenorphine (right) in humans. The response 




The dose–average drug effect relationships are shown in figure 5. For fentanyl there was a 
steep dose–effect relationship, with increasing values at increasing fentanyl doses (P < 0.001). 
In contrast, for buprenorphine the average drug effect did not differ among doses. 
 
Side Effects. The one subject dosed with 7.1 µg.kg-1 fentanyl developed apnea within 4 min 
of infusion with a drop in SpO2 to 68%. She was instructed to take regular breaths and 100% 
inspired oxygen was given. This resulted in a quick return to SpO2 values > 90%. The apneic 
episode lasted about 8 min after which breathing resumed with PETCO2 values > 7 kPa. We 
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did not remove the ventilation data points at a higher PETCO2 level than targeted in the study. 
One subject receiving 8.6 µg.kg-1 buprenorphine developed severe nausea about 60 min after 
the infusion of the drug. During this period of nausea (lasting about 30 min) he had a 
hyperventilatory response. Time to end of effect was set at 420 min. We decided to leave the 
data as they were as it did not affect the peak effect and time to peak effect data. It did cause 
underestimation of the average drug effect of this subject, however. All other side effects 
were mild ranging from mild nausea to sedation. Sedation developed in most subjects after 
having received an opioid but was marked after 8.6 µg.kg-1 buprenorphine. BIS values were 
> 90 during respiratory measurements in all subjects, irrespective of the opioid dose. 
Decreases in BIS did occur in between respiratory measurements and were always related to 







































Figure 5. Average drug effect for fentanyl (left) and buprenorphine (right) in humans. Analysis of variance 




The effects of both opioids on PaCO2 are shown in figures 6 and 7. As predicted the increase 
in PaCO2 after the infusion of fentanyl was rapid with significant effects apparent just 5 min 
after the initiation of the fentanyl infusion. 
 
After fentanyl, a significant dose–effect was observed at times t = 5, 10 and 15 min (P = 0.01) 
with an almost linear dose–response relationship (figure 6). At t = 20 min, a maximum in 
respiratory depression (PaCO2 7.5 kPa) was observed at all doses tested (fentanyl versus 
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vehicle, P < 0.001; no significant differences among the fentanyl doses). The changes in 























































Fentanyl dose (µg.kg-1)                                         Fentanyl dose (µg.kg-1)  
 
Figure 6. Fentanyl dose–response relationship obtained in rats at times t = 5, 10, 15 and 20 min after 
the initiation of the fentanyl infusions. A linear dose–response relationship was observed at times t = 5, 
10 and 15 min (P = 0.01). After 20 min, maximum effect was reached at all fentanyl doses with no 
significant differences among the fentanyl doses. 0 µg.kg-1 is vehicle. To guide the eye, linear 
regression curves are plotted through the data (continuous lines) at times t = 5, 10 and 15 min.  
 
 
Irrespective of the time at which measurements were obtained and dose, buprenorphine 
showed a relatively small increase in PaCO2 of 1–1.5 kPa (buprenorphine versus vehicle, 
P < 0.05; no significant differences among the buprenorphine doses). This indicates that a 
plateau in respiratory depression occurred at a dose of 0.1 mg.kg-1 buprenorphine causing an 





In humans and rats, we studied two potent opioids, buprenorphine and fentanyl, and observed 




good correspondence leading to similar conclusions. In contrast to fentanyl, buprenorphine 
showed a ceiling (or apparent maximum) effect in its ability to cause respiratory depression.  
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Figure 7. Buprenorphine dose–response relationship obtained in rats at times t = 30, 120, 270 and 
390 min after the initation of the buprenorphine infusions. At all measured times a plateau in effect 
was observed at doses > 100 µg.kg-1 (100, 300, 1000 and 3000 µg.kg-1 buprenorphine versus vehicle, P 
< 0.01; no significant differences among the buprenorphine doses). 0 µg.kg-1 is vehicle.  
 
 
The PETCO2 was controlled within 0.1 kPa (mean SD of PETCO2 fluctuations). In some cases 
deviations from target PETCO2 greater than 0.4 kPa did occur related to the short periods of 
relative hyperventilation following apnea (see figure 2). While these deviations from target 
PETCO2 may have influenced the time profile of individual curves and underestimated the 
average drug effect, we do not believe that the final conclusions of the study were influenced 
significantly. In those instances that apnea did occur we coached the subjects to take deep 
breaths. Coaching may have activated behavioral control of breathing and consequently may 
have influenced the study results (average drug effect).13 However, the influence of 3–8 min 
of coaching during apnea on a 7-h experiment was minimal.  
 
Buprenorphine 
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We were able to successfully coach the subjects through the episode of apnea after 2.9 and 
4.3 µg.kg-1 fentanyl. However we felt that the prolonged period of apnea with low SpO2 
observed in the first subject dosed with 7.1 µg.kg-1 fentanyl was unacceptable and hence 
decided to restrict our study to a maximum fentanyl dose of 4.3 µg.kg-1. Similarly, in rats, we 
had observed in a pilot study that short-term infusions of fentanyl but not buprenorphine 
caused the death of several of our animals. To overcome this problem we infused both tested 
drugs over 20 min in the rats. The different method of drug administration between humans 
and rats may have resulted in differences in plasma drug time profiles. 
 
In the human study we focused our data analysis on two measures of respiratory outcome: 
peak effect and the average drug effect. Average drug effect divided by the duration of effect 
is considered a weighted average of a response,12 and allows comparisons among drug doses 
when no pharmacokinetic data are available. Although both measures (peak effect and 
average drug effect) are related to the pharmacokinetics and pharmacodynamics of the infused 
drug, they represent two distinct features of the drug that complement each other. Peak effect 
is related to the rise of the opioid concentration in the brain compartment, subsequent 
attachment to the opioid receptor and neuronal dynamics. The average drug effect is related to 
the accumulation of the drug within the brain compartment, receptor kinetics (association and 
more important dissociation) and neuronal dynamics and gives an indication of the opioid’s 
respiratory efficacy. Both indices showed great variability (see SD’s in figures 4 and 5). The 
early effects were especially variable, which may be due to variability in the central volume 
of distribution, transit and uptake of the drug in the lungs (fentanyl)14 and passage across the 
blood brain barrier.  
 
In humans, the relationships between buprenorphine dose and peak effect and average drug 
effect were non-linear. These findings contrast with the observations that the relationships of 
peak effect and average drug effect and dose of fentanyl were linear over the dose range from 
0 to 4.3 µg.kg-1. We remain uninformed on the effect of fentanyl at doses > 4.3 µg.kg-1 with 
only data from one subject at 7.1 µg.kg-1. However, when we take into account the data from 
this one subject together with the animal data it is evident that also at the higher fentanyl 
doses, the human dose–response curve has linear characteristics. Only few studies 
systematically addressed the issue of buprenorphine-induced respiratory depression in 
humans. Comparison of our data with these studies is difficult. In our studies we used 
isocapnia (constant end-tidal PCO2) and measured ventilation. Other studies used either no 
control for carbon dioxide, a constant inspired CO2 concentration or less informative 
measures such as respiratory rate. In two studies, Walsh et al. assessed the effect of           
0.5–32 mg sublingual buprenorphine on respiratory rate and oxygen saturation.15,16 They 
observed a non-linear dose–response curve with a plateau arising between 0.4 and 0.8 mg. 
Despite the fact that neither respiratory rate nor oxygen saturation are valid markers of 
respiration, the results of the studies of Walsh et al. do give a qualitative suggestion of 
buprenorphine’s behavior in humans. Our data, obtained at isocapnia, give a quantitative 
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indication of the occurrence of ceiling in buprenorphine-induced respiratory depression at 
intravenous doses of ≥ 2 µg.kg-1. 
 
Despite the overt differences in methodology between the human and animal studies, the 
results of the studies were similar. In the animal studies we used arterial PCO2 as a surrogate 
measure of minute ventilation. The measured PaCO2 in our studies is not only determined by 
the respiratory depression per se, but also by its complex interaction with ventilation. The 
increase in PaCO2 has a drug-dependent stimulatory effect on breathing causing the (drug-
dependent) elimination of CO2 from the lung. We therefore may have underestimated any 
respiratory depression observed in the animals. An example of the underestimation of 
respiratory depression in human studies performed under poikilocapnic conditions (i.e., end-
tidal PCO2 was not kept constant) is the observation by Mildh et al. of a very high EC50 value 
(drug concentration causing 50% effect) for fentanyl-induced respiratory depression 
(6.1 ng.ml-1).10 In that study ventilation was measured and fentanyl was infused slowly 
allowing the accumulation of CO2 which prevented the occurrence of severe respiratory 
depression and apnea. Bouillon et al. addressed this issue by using indirect–response models 
to calculate the EC50 and taking into account both drug and CO2 effects.17 Although 
calculation of the EC50 is not directly possible from our study, using pharmacokinetic data 
from the literature, we were able to estimate a value of 1.5 ng.ml-1 which is a factor of 4 
smaller than the value of Mildh et al. Taken into account all of the above, we do not believe 
that our animal data lack importance. Like the studies of Walsh et al., these data give 
qualitative proof of the behavior of both tested opioids. 
 
In humans, the occurrence of apnea shortly after the 90-s infusion of high dose fentanyl 
(≥ 200 µg) is related to the rapid increases in blood fentanyl concentration, its rapid passage 
across the blood–brain barrier (the fentanyl blood–effect site equilibration half-life is about 
5 min),18 with consequently high brain concentrations and almost immediate attachment to the 
µ-opioid receptor. This caused rapid depression of respiratory neurons expressing the µ-opioid 
receptor (peak respiratory effect after fentanyl occurred at 4.8 min). Buprenorphine, like 
fentanyl, is highly lipophilic with a relatively rapid passage across the blood–brain barrier. 
However, in contrast to fentanyl, buprenorphine displays slow opioid receptor association and 
dissociation kinetics.19 This may have prevented rapid changes in ventilation in our 
population despite relatively high brain concentrations (peak respiratory effect after 
buprenorphine occurred at 117 min). 
 
It is generally believed that both fentanyl and buprenorphine produce their intended effect 
(analgesia) via an action at the µ-opioid receptor gene (OPRM1) product. Using exon 2 Oprm 
knockout mice, we observed that the µ-opioid receptor is the source of morphine-induced 
antinociception and respiratory depression.20,21 Involvement of other opioid receptors (κ-, δ- 
or ORL1 receptors) in morphine-induced respiratory depression seems unlikely. We believe 
this also holds true for other opioids such as fentanyl. Hence, we postulate that the effect of 
fentanyl at the µ-opioid receptor is exclusively responsible for the (almost-linear) dose–
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response relationship found in our volunteers and animals (figures 4–6). In rats, the finding of 
a maximum effect of fentanyl 20 min after the start of the infusion shows the maximum effect 
on respiration that is possible in animals (fentanyl doses ≥ 90 µg.kg-1 are fatal). Our human 
(average drug effect, figure 5) and animal data indicate that fentanyl is a full agonist at the 
µ-opioid receptor with high intrinsic activity. The non-linear buprenorphine dose–response 
relationship we observed is in agreement with earlier human and animal studies on its 
respiratory effect.7-9 Especially rat data systematically show ceiling in buprenorphine-induced 
respiratory depression at doses above 0.1 mg.kg-1.7,8 In rhesus monkeys a similar observation 
was made for doses greater than 1.0 mg.kg-1.9 This latter study is of interest since it measured 
steady-state minute ventilation at a fixed inspired CO2 concentration of 5%. Partial agonism 
of buprenorphine at the µ-opioid receptor is generally held responsible for the ceiling 
phenomenon.4,7 Partial agonism indicates a partial (respiratory) effect despite full µ-opioid 
receptor occupancy. Recently, Lutfy et al. proposed a different mechanism for the non-linear 
dose-response.5 They showed that buprenorphine (but not morphine) given to mice activates 
ORL1 receptors compromising antinociception mediated via µ-opioid receptors. Extrapolation 
of these animal data on antinociception to our respiratory studies would suggest that 
buprenorphine’s action at the ORL1 receptor would cause the reduction of respiratory 
depression from buprenorphine’s action at the µ-opioid receptor. In this respect 
buprenorphine would act as a respiratory stimulant at the ORL1 receptor. Just one study 
addressed the influence of the ORL1 receptor on respiration.22 In an in vitro preparation of the 
newborn rat brainstem activation of the ORL1 receptor produced depression of respiratory 
rhythm generation. This observation does not support the hypothesis of involvement of the 
ORL1 receptor in the development of ceiling in buprenorphine’s respiratory effect. The 
current data are very scanty and further studies are required to elucidate the involvement of 
the ORL1 receptor in opioid induced respiratory depression. 
 
The observation of ceiling in buprenorphine-induced respiratory depression has contributed to 
the notion that buprenorphine’s respiratory effects are limited.1 (Significant or fatal 
respiratory depression has only been reported when buprenorphine was combined with 
sedative drugs such as benzodiazepines.23) However, buprenorphine’s safety profile should be 
considered against the background of its analgesic profile. For example, if a ceiling in 
respiratory depression coincided with ceiling in analgesia, then the value of buprenorphine 
would be limited in clinical practice. While there is evidence from animal data of the 
occurrence of a ceiling or even a bell-shaped response curve in the analgesic effect of 
buprenorphine (at doses > 1.0 mg.kg-1),5,7,24 there are no good (placebo-controlled, 
randomized) human studies available. Our data and those of others obtained in rodents 
indicate that ceiling in respiratory effect occurs at a much lower dose (0.1 mg.kg-1) than 
ceiling in analgesic effect (1.0 mg.kg-1) which indicates the relative safety of buprenorphine 
combined with its ability to produce effective analgesia in these animals.5,7-9,24 Before we can 
extrapolate these claims to humans we need good clinical studies to determine whether there 
is a ceiling for analgesia and assess the dose at which it occurs. Our study can not address the 
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3 Buprenorphine Induces Ceiling in Respiratory Depression but 
Not in Analgesia 
 
 
Buprenorphine is a semi-synthetic opioid in clinical use for treatment of acute and chronic 
pain since 1979.1 Buprenorphine is a potent analgesic with agonistic activity at the µ-opioid 
receptor and antagonistic properties at the κ-opioid receptor.2 Human studies show that 
buprenorphine behavior is typical of µ-opioid receptor agonists, with respect to its intended 
effect (potent and long-lasting analgesia) and side effects (for example sedation, nausea, 
delayed gastric emptying and respiratory depression).2,3 In a previous study, in a group of 
healthy volunteers buprenorphine-induced respiratory depression demonstrated ceiling (or an 
apparent maximum effect) at doses > 0.1 mg (per 70 kg).4 Ventilation at a fixed end-tidal 
PCO2 reached maximum peak depression of about 50% of baseline. Buprenorphine’s 
behavior contrasts that of fentanyl, which showed irregular breathing and apnea at high dose 
(> 200 µg per 70 kg). These findings suggest a greater margin of safety for buprenorphine 
relative to other potent opioids frequently used to treat severe acute and chronic pain. 
However, buprenorphine’s safety profile must be considered against the background of its 
analgesic profile. For example, would ceiling in respiratory depression coincide with ceiling 
in analgesia then the value of buprenorphine would be limited in clinical practice. Recently 
we observed in rats the occurrence of ceiling in buprenorphine’s respiratory effect while no 
ceiling was observed in buprenorphine’s antinociceptive behavior.4,5 There are no good 
experimental human studies available on buprenorphine’s analgesic behavior at doses causing 
ceiling in respiratory effect. To address this important issue we assessed the effect of two 
doses of intravenous buprenorphine (0.2 and 0.4 mg/70 kg) on respiration and analgesia in a 
group of young and healthy volunteers. Previous studies indicated that the respiratory effect 





Twenty volunteers (10 men, 10 women; aged 22–35 years, weight 62–92 kg) participated in 
the protocol after approval was obtained from the local Human Ethics Committee. All 
subjects were healthy and did not have a history of illicit substance abuse or smoking. They 
were asked to refrain from stimulants and depressant substances for at least 12 h before the 
study. Each subject participated once. After arrival in the laboratory the subjects were 
familiarized with the pain test and breathing apparatus for about 60 min. 
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Half of the subject group (n = 10, 5 men, 5 women) received 0.2 mg (per 70 kg) 
buprenorphine i.v., the other half 0.4 mg (per 70 kg) buprenorphine i.v. Buprenorphine 
(Reckitt Benckiser Healthcare Ltd, Hull, UK) was infused slowly over 90 s. 
 
Respiration 
To study ventilation we used the dynamic end-tidal forcing technique.6 This technique 
enables us to force end-tidal PCO2 (PETCO2) and end-tidal PO2 (PETO2) to follow a specific 
pattern in time. In this study we clamped the PETCO2 and PETO2 to 7 kPa and 14.5 kPa, 
respectively, throughout the studies. The subjects were comfortably positioned in a hospital 
bed and breathed through a face mask, positioned over nose and mouth (a nose clip was not 
used). The face mask received fresh gas (45 l.min-1) from a gas mixing system consisting of 
three mass flow controllers (Bronkhorst High-Tech BV, Veenendaal, The Netherlands) for the 
delivery of oxygen, carbon dioxide and nitrogen. A personal computer provided control 
signals to the mass flow controllers allowing the adjustment of the inspired gas concentrations 
to obtain the desired end-tidal concentrations. The in- and expired gas flows were measured at 
the mouth using a pneumotachograph connected to a pressure transducer (Hans Rudolph, 
Wyandotte, MI, USA) and electronically integrated to yield a volume signal. The volume 
signal was calibrated with a motor-driven piston pump. The oxygen and carbon dioxide 
concentrations were measured using a gas monitor (Multicap, Datex, Helsinki, Finland); a 
pulse oximeter (Masimo, Irvine, CA, USA) continuously measured the oxygen saturation 
(SpO2) of arterial hemoglobin with a finger probe. All relevant variables (minute ventilation, 
SpO2, PETCO2 and PETO2) were available for on-line analysis and stored on a breath-to-breath 
basis for further analysis. 
 
At several times respiration was measured: t = -30 min (30 min before the drug was infused) 
and at times t = 15, 75, 140, 180, 240, 300, 360, 420 and 480 min after the infusion of 
buprenorphine. The respiratory studies started after ventilation (at a fixed PETCO2 of 7 kPa) 
had reached a steady state. Next the mean value of 10 consecutive breaths was calculated and 
used in the data analysis. Generally no more than 7 minutes were needed before a 
measurement at steady state was obtained. In between respiratory measurements the subjects 
were taken off the mask and analgesia testing was performed. 
 
Analgesia 
Acute pain was induced by an electrical current through two surface electrodes (Red Dot, 3M, 
London, Ontario, Canada) placed on the skin overlaying the tibial bone (shin bone) of the left 
leg.7 The electrodes were attached to a computer interfaced current stimulator (CICS, Leiden 
University Medical Center, Leiden, The Netherlands). The intensity of the noxious 
stimulation was increased from 0 mA in steps of 0.5 mA per 1 s. The stimulus train consisted 
of a square-wave pulse of 0.2 ms duration applied at 10 Hz and had a cutoff at 128 mA. The 
subjects were instructed to press a button on a control panel when no further increase in 
stimulus intensity was acceptable (pain tolerance). Upon pressing the pain tolerance button, 
the stimulus train ended. This procedure was performed three times prior to drug infusion (the 
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mean of which was used as baseline value) and at fixed times after drug infusion (at times 
t = 5, 10, 45, 80, 110, 130, 165, 210, 270, 330, 390, 450 and 490 min after the drug infusion). 
The current at which pain tolerance occurred was automatically collected and stored on the 
hard disc of a computer for further analysis. The involvement of the observers in the pain 
assessments was restricted to training the subjects and to the initiation of the stimulus train 
during the studies. 
 
Data Analysis 
Data analysis was performed on the absolute respiration and pain tolerance values and on the 
values relative to baseline (i.e., ∆ventilation and ∆pain tolerance). Data are reported as mean 
(SD). Statistical analysis was performed using SigmaStat 3.1 (Systat Software, Inc., Point 
Richmond, CA, USA). A two-way repeated measures analysis of variance was applied to 
detect a significant difference of buprenorphine dose on respiration or analgesia and to detect 






All subjects completed the study without major side effects. Most prominent side effects were 
nausea and vomiting that occurred in 80% and 40% of subjects, respectively. 
Nausea/vomiting remained untreated throughout the study period. 
 
Respiration 
The two buprenorphine doses had a similar effect on ventilation. Baseline ventilation at a 
PETCO2 of 7 kPa did not differ between the two dose groups:  24.2 (2.3) l.min-1 in the 0.2 mg 
versus 23.5 (1.9) l.min-1 in the 0.4 mg buprenorphine group. After infusion of the drug 
ventilation showed a rapid decline and reached peak depression between t = 150 and 180 min 
(see figure 1). This effect was dose-independent with respect to timing and magnitude:          
at peak respiratory depression ventilation was 13.1 (1.8) l.min-1 (0.2 mg) versus 
12.0 (1.3) l.min-1 (0.4 mg, n.s.). The overall effect of buprenorphine on ventilation was dose-
independent over the 8 hours of the study: 0.2 versus 0.4 mg, P > 0.05. No sex difference was 
observed (factors sex and the interaction term between sex and dose, P > 0.05). 
 
Analgesia 
A significant increase in analgesia was observed going from 0.2 to 0.4 mg buprenorphine. 
Baseline pain tolerance currents did not differ between the two groups: 16.3 (3.9) mA 
(0.2 mg) versus 15.0 (2.6) mA (0.4 mg) (n.s.). At 0.2 mg buprenorphine a small short-lived 
analgesic effect was observed with a maximum increase in pain tolerance current of 
6.7 (2.8) mA occurring at t = 75 min (figure 2). Peak analgesic effect was 41% above baseline 
current. In contrast, 0.4 mg buprenorphine caused a large and long-lived analgesic effect with 































Figure 1. Influence of intravenous buprenorphine, 0.2 and 0.4 mg (per 70 kg), on inspired minute 
ventilation at a fixed PETCO2 of 7 kPa in healthy volunteers (each dose: n = 8). The influence of the 





























Figure 2. Influence of intravenous buprenorphine, 0.2 and 0.4 mg (per 70 kg), on pain tolerance in 
healthy volunteers (each dose: n = 8). Values are the increase in currents to achieve pain tolerance 
relative to baseline pain tolerance currents. A significant increase in analgesia is observed going from 
0.2 to 0.4 mg buprenorphine. 
                                      ime (min)
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Peak analgesic effect was 159% above baseline current (P < 0.01 versus 0.2 mg). The overall 
effect of buprenorphine on analgesia was dose-dependent over the 8 hours of the study 
(0.2 versus 0.4 mg, P < 0.01). No sex difference was observed (factors sex, sex × dose, 





In the current study we examined the effect of 0.2 and 0.4 mg intravenous buprenorphine 
(dosed per 70 kg) on ventilation and on analgesia in healthy volunteers. We observed that 
doubling the dose of buprenorphine increased its peak analgesic effect by a factor of 3.5 (from 
6.7 mA to 23.8 mA). In contrast, the timing and magnitude of respiratory depression remained 
unchanged by doubling the buprenorphine dose (compare figures 1 and 2). These data suggest 
that buprenorphine displays a plateau for respiratory depression over a dose range where no 
plateau in analgesic effect is observed. However, before definite conclusions can be drawn 
our data needs to be viewed in context, that is against the background of a more extensive 
dose–response relationship. This is important taken into account the observation in some 
animal studies of a bell-shaped (inverse U-shaped) dose-response relationship for 
buprenorphine’s analgesic effects.8,9 In a previous study we assessed the effect of 0.05, 0.1, 
0.3 and 0.6 mg buprenorphine on breathing in a similar study population.4 We observed a 
ceiling effect in peak respiratory depression of the drug at doses > 0.1 mg. Although the 
design of the previous and current studies differs with respect to the duration of measurements 
(in contrast to the current study, we previously measured breathing continuously for 90 min), 
we were able to combine these two data sets on peak respiratory depression (figure 3). The 
continuous line in figure 3 is the data fit using a sigmoid Emax model to all data presented 
(including the data from the current study). The broken line is the data fit using a decaying 
exponential model to the complete data set. Both models give similar results, that is, that the 
0.3 and 0.6 mg buprenorphine data is on the flat part of the dose–response relationship, about 
50% of baseline ventilation. To the best of our knowledge, an extensive dose–response 
relationship of the analgesic properties of buprenorphine in humans is not available in the 
literature. We recently assessed the analgesic effect of 0.05, 0.1 and 0.3 mg i.v. buprenorphine 
over time in 15 healthy young volunteers using our electrical pain model (Dahan, unpublished 
observation). In figure 4 we plotted the mean increase in current to achieve pain tolerance 
(relative to baseline pain tolerance current) versus dose and added the data from the current 
study. A dose-dependent increase in analgesic effect is observed without any sign of ceiling. 
We believe that this is sufficient proof to state that buprenorphine displays ceiling in 
respiratory depression over a dose range (0.05–0.4 mg) without causing any ceiling in 
analgesic effect. Evidently, this is true for the applied acute pain model and the subset of 
subjects that we used (young and healthy volunteers using no co-medication). Finally, we 
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Figure 3. Human buprenorphine dose–respiratory response (peak respiratory depression) relationship. 
Values are mean. Open symbols: data from ref. 4; closed symbols: data from the current study. Both a 
sigmoid Emax model (continuous line) and a decaying exponential model (broken line) were fitted to 
the data. Both model fits indicate that the 0.3 and 0.6 mg buprenorphine data are on the flat part of the 
dose–response relationship. 
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Figure 4. Human buprenorphine dose–analgesic response (peak analgesic effect) relationship. Data are 
mean. Values are relative to baseline: a value of 1.5 indicates a 50% increase in current to achieve pain 
tolerance. 0 mg per 70 kg is placebo (0.9% NaCl). Open symbols: data from unpublished observations; 
closed symbols: data from the current study. To guide the eye a power model was fitted to the data.24 
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Differential Effect of Buprenorphine on Analgesia and Respiration 
Our data suggest that buprenorphine is a full agonist at µ-opioid receptors (MOR’s) involved 
in pain processing but a partial agonist at MOR’s involved in respiratory depression. Partial 
agonism indicates a partial effect despite full MOR occupancy. These findings are in 
agreement with rat data from our laboratories and with some clinical studies which show the 
absence of ceiling effect for analgesia (tested at much greater buprenorphine doses than tested 
by us) and the ability to produce 100% pain relief despite the observation of ceiling for 
properties other than analgesia (such as sedation and the decrease in respiratory frequency).2,4 
Buprenorphine behaves very differently from other opioids (full agonists with respect to 
respiratory effect and analgesia) such as morphine and fentanyl. For example, we previously 
measured the respiratory depressant effect of morphine simultaneously with morphine’s 
antinociceptive effects in humans.7 We observed that over the concentration range that caused 
a systematic increase in analgesia, morphine caused concentration-dependent respiratory 
depression without any plateau or ceiling.  
 
It is possible that differences in receptor density may be the cause of the differential 
buprenorphine effect at the two typical µ-opioid end points studied by us. For example, 
Garrido et al. showed in rats that progressive MOR knockdown (i.e., the reduction in MOR 
binding sites) with the irreversible MOR antagonist β-funaltrexamine, caused a marked 
decrease in alfentanil efficacy.10 Alfentanil transformed from a full MOR agonist into a partial 
agonist at reduced MOR availability. It may then be argued that MOR density is greater at 
pathways in the central nervous system concerned with processing pain than at the respiratory 
centers in the brainstem.  
 
Another explanation for buprenorphine’s behavior may be found in a difference in the 
agonist/MOR/G-protein/β-arrestin complex in pain and respiratory neurons. Opioid receptors 
belong to the superfamily of seven-transmembrane G-protein-coupled receptors which bind to 
G-proteins and the regulatory protein β-arrestin upon activation.11 Raehal et al.12 showed that 
genetic disruption of the β-arrestin type 2 (βarr2) gene (βarr2 knockout mice) attenuated the 
respiratory depression (and acute constipation) caused by morphine. In contrast, morphine-
induced antinociception was augmented in the βarr2 knockout mice.13 The authors 
hypothesized that β-arrestin may play an important G-protein independent role in signal 
transduction via MOR’s that lead to respiratory depression (and gastrointestinal transit 
inhibition) but not via MOR’s that lead to analgesia. G-protein independent but β-arrestin 
dependent activation has been observed for other receptors of the seven-transmembrane 
receptor superfamily, such as the β2-adrenergic receptor.14 Following the reasoning of Raehal 
et al.12 and taking into account our data, this suggests that MOR activation of a G-protein 
independent signal transduction pathway is ligand specific: some ligands (such as fentanyl 
and morphine) cause changes in neuronal physiology fully dependent on G-protein activation 
causing full MOR responses, while others (such as buprenorphine) activate the β-arrestin 
protein with diminished responses. We hypothesize that signal transduction due to 
buprenorphine-activation of MOR’s expressed on respiratory neurons is via β-arrestin 
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mediation and not via G-protein activation. Interestingly, morphine’s active metabolite 
morphine-6-glucuronide (M6G) displays significantly less respiratory depression than 
morphine (i.e., a rightward shift of the dose–response relationship).15 A shared difference in 
the structure of M6G and buprenorphine with morphine is modification of the hydroxyl group 
at position C6 of the morphine molecule (morphine: C6–OH, buprenorphine: C6–O–CH3  and 
M6G: C6–glucuronide). Possibly this modification at C6 may be the cause for the reduced 
effect at MOR’s expressed on respiratory neurons (cf. reference 16). Further studies are 
needed to clarify this important issue. 
 
In contrast to our previous study,4 we now can address the issue of buprenorphine’s 
respiratory safety in light of its analgesic properties. Opioid-induced respiratory depression is 
related to overdosing, concurrent sedation/sleep, co-medication, the periodic nature of pain 
and underlying disease. The frequency of serious respiratory events related to opioid use 
remains poorly reported and probably poorly studied. In chronic cancer and non-cancer pain 
patients, respiratory complications are often erroneously taken for progression of disease and 
sometimes accepted –and hence unreported– in the light of the poor prognosis of the patient. 
However, a series of recent case-reports on fentanyl-induced severe respiratory depression 
and death in old and relatively healthy young patients has lead to several warnings related to 
the use of fentanyl patches for treatment of chronic pain.17-20 The question is whether 
buprenorphine can make a difference, or –in other words– whether the use of buprenorphine 
in pain patients will cause less respiratory events than commonly used potent opioids such as 
morphine and fentanyl. Our data support the notion that since buprenorphine’s respiratory 
effects are limited, buprenorphine has an advantage over other opioids such as fentanyl and 
morphine which do not show ceiling at high dose but eventually cause breathing instability 
and apnea. However, whether this advantage persists under specific conditions such as old 
age, (lung) disease and use of co-medication needs further study. In opioid-addicts acute co-
administration of buprenorphine and benzodiazepines is sometimes associated with fatal 
respiratory depression.21  
 
 
Critique of Methods 
We used our pain model as a pharmacological tool and did not intend to simulate clinical 
(acute or chronic) pain. We previously used this acute pain model (electrical transcutaneous 
stimulation of the skin) successfully to study the antinociceptive effects of morphine and 
M6G.7,22 The results of these studies were comparable with clinical observations on morphine 
and M6G pain relief in acute and chronic pain patients with respect to analgesia and drug 
potency. Since the healthy volunteers tested in our studies were without pain or inflammation, 
the term antinociception seems a more appropriate description of the opioid behavior in the 
acute pain test. The choice of the term analgesia throughout this paper was taken –somewhat 
arbitrarily– to make a distinction from animal studies. In the current study we combined 
respiratory and analgesia measurements. 
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It may be argued that pain measurement may interfere with respiratory measurements and vice 
versa. This is true, pain testing may have a significant effect on breathing, often causing 
hyper- and/or hypoventilatory responses due to activation of behavioral respiratory drives;23 
and hypercapnia has been shown to influence pain testing.24 We tried to minimize the 
complex interactive effects of pain testing and respiratory measurements by allowing ample 
time between measurements, but we can not exclude some mutual disturbing effects on both 
systems.  
 
We were unable to detect significant sex differences in buprenorphine’s respiratory and 
analgesic responses, although there was a clear trend in the data (P = 0.09) with greater 
responses in women. Our current study was not designed to examine sex differences, such as 
observed earlier for morphine.25,26 Post-hoc power analysis indicated that 20 subjects 
(10 men/10 women) were needed to reveal a sex difference in analgesia after 0.4 mg 
buprenorphine at the P = 0.05 level. 
 
In conclusion, we tested two incremental intravenous doses of buprenorphine (0.2 and 
0.4 mg) on pain relief and respiratory depression in a group of healthy young volunteers. We 
observed that while buprenorphine’s analgesic effect increased significantly, respiratory 
depression showed a similar magnitude and timing for the two doses tested. Taking into 
account additional data from our laboratory we conclude that buprenorphine displays ceiling 
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4 Naloxone-Reversal of Opioid-Induced Respiratory Depression 
with Special Emphasis on Buprenorphine 
 
 
Long-acting opioids are important tools in the treatment of postoperative acute pain and 
chronic cancer and non-cancer pain. When selecting one of the available compounds, not only 
the analgesic properties but also the safety profile of the drug needs to be considered. In 
general, opioids are well tolerated. Among the opioid-typical side effects, however, 
respiratory depression is of special importance because of the risk of fatal outcome for the 
patient.  
 
Buprenorphine is a potent analgesic (100 times more potent than morphine) with µ-agonistic, 
ORL1-agonistic and κ-antagonistic opioid properties.1 In patients, buprenorphine is used for 
treatment of acute and chronic pain via various administration modes, such as intravenous 
(i.v.), transdermal, sublingual, epidural or spinal administration. In humans, buprenorphine 
behaves as a typical µ-opioid receptor agonist showing analgesia, euphoria, sedation, 
respiratory depression and pupillary constriction.1,2 Buprenorphine has high affinity for opioid 
receptors and slow receptor association and dissociation kinetics as compared to other 
opioids.3 After an intravenous infusion of 0.2–0.4 mg/70 kg the duration of action of 
buprenorphine is about 6 to 8 hours. Data obtained in opioid-naïve volunteers indicate that 
buprenorphine causes dose-dependent respiratory depression which levels off at greater 
buprenorphine doses (i.e., plateau or ceiling in respiratory effect).4  
 
Surprisingly few studies have addressed the ability to reverse the respiratory effects of opioids 
in general and buprenorphine in specific. Just two studies from the literature published in the 
1980’s as well as some anecdotal data suggest that the respiratory depression from 
buprenorphine is resistant to antagonism by naloxone.5-7 While relatively low bolus doses of 
intravenous naloxone had no effect, high doses (2.5 to 10 mg) caused only partial reversal of 
buprenorphine’s respiratory effects. These results may be explained by the short duration of 
action of a bolus dose of naloxone resulting from a rapid elimination combined with the high 
affinity of buprenorphine for µ-opioid receptors. Consequently, a bolus dose of naloxone may 
be unable to displace buprenorphine from the opioid receptors. The buprenorphine/naloxone 
data contrast data on the ability to reverse fentanyl-induced respiratory depression, which is 
considered relatively easy. Short naloxone infusions up to 0.4 mg cause full reversal of 
fentanyl-induced respiratory depression in patients during halothane/nitrous oxide anesthesia.8 
 
We performed a series of experiments to study the influence of naloxone on buprenorphine-
induced respiratory depression. Our aim was to obtain a naloxone-dosing regimen that would 
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cause full reversal of buprenorphine-induced respiratory depression. Initially (Study 1) we 
assessed the effect of 0.8 mg naloxone (or placebo) on 0.2 mg i.v. buprenorphine-induced 
respiratory depression in healthy volunteers. In a subsequent study (Study 2) we explored 
which naloxone dose causes full reversal of 0.2 mg i.v. buprenorphine-induced respiratory 
depression. In order to do so we tested various naloxone doses in the range from 0.5 to 7 mg 
in separate subjects. In another study (Study 3) we assessed the effect of a continuous 
naloxone (or placebo) infusion on 0.2 and 0.4 mg i.v. buprenorphine-induced respiratory 
depression. Finally, in order to compare the results of studies 1–3 we assessed the effect of 
just 400 µg naloxone (or placebo) on 0.15 mg.kg-1 i.v. morphine-induced respiratory 
depression (Study 4) and 4 µg.kg-1 naloxone on alfentanil-induced depression of the 
ventilatory response to hypoxia (Study 5). We hypothesized that while 300–400 µg naloxone 
was sufficient to fully reverse morphine- and alfentanil-induced respiratory depression, much 
greater doses and a continuous infusion are needed to reverse buprenorphine-induced 





A total of ninety-nine male and female subjects (age range 20–30 years, weight 54–93 kg) 
participated in the studies after approval of the protocols was obtained from the local Human 
Ethics Committee. We obtained oral and written consent. All subjects were healthy and did 
not have a history of illicit drug use or mental disease. All women were taking oral 
contraceptives. Subjects were asked to have a normal night of sleep and not to eat or drink for 
at least 6 h prior to the study. They were comfortably seated in a hospital bed for the duration 
of the study.  
 
Respiration 
In- and expired gas flows were measured with a pneumotachograph (Hans Rudolph, 
Wyandotte, MI, USA) connected to a pressure transducer and electronically integrated to 
yield a volume signal. The volume signal was calibrated with a motor-driven piston pump 
(stroke volume 1000 ml, at a frequency of 20.min-1). The pneumotachograph was connected 
to a T-piece. One arm of the T-piece received a gas mixture with a flow of 45 l.min-1 from a 
gas mixing system, consisting of three mass flow controllers (Bronkhorst High-Tech BV, 
Veenendaal, The Netherlands) with which the flow of O2, CO2 and N2 could be set 
individually at a desired level. A personal computer provided control signals to the mass flow 
controllers so that the composition of the inspired gas mixtures could be adjusted to force 
end-tidal oxygen and carbon dioxide concentrations (PETO2 and PETCO2) to follow a specified 
pattern in time, independent of the ventilatory response (i.e., dynamic end-tidal forcing).9 In 
the studies 1–4, PETCO2 was clamped at 7.0 kPa throughout the measurements (about 1 kPa 
above resting values), while PETO2 was maintained at a normoxic value of 14.5 kPa. In 
study 5, PETCO2 was clamped at 7.0 kPa and PETO2 lowered to 6.0 kPa for 3 min. The O2 and 
CO2 concentrations and the arterial Hb-O2 saturation (SpO2) were measured with a gas 
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monitor near the mouth (Multicap, Datex, Helsinki, Finland) and a pulse oximeter (Masimo, 
Irvine, CA, USA) using a finger probe, respectively. The gas monitor was calibrated with gas 
mixtures of known composition delivered by a gas-mixing pump (Wösthoff, Bochum, 
Germany). PETCO2, PETO2, inspired minute ventilation and SpO2 were collected on a breath-
to-breath basis and stored on disc for further analysis.  
 
Study Design and Data Analysis 
The studies were placebo-controlled and had a double blind design (except study 5, see 
below). The local pharmacy delivered the buprenorphine hydrochloride (Reckitt Benckiser 
Healthcare Ltd, Hull, UK), alfentanil hydrochloride (Janssen-Cilag BV, Tilburg, The 
Netherlands), morphine hydrochloride and naloxone hydrochloride (both manufactured by the 
local pharmacy), and placebo (NaCl 0.9%). Randomization and preparation of the syringes 
was performed by a physician not involved in the study using randomization lists obtained 
from www.randomization.com. All buprenorphine and naloxone doses are per 70 kg. All 
bolus infusions were given over 90 s. Each subject participated once in any of the studies. 
Values are reported as mean ± SEM, unless otherwise stated. 
 
Study 1 
Sixteen subjects participated in this study. All received 0.2 mg buprenorphine i.v. (at time 
t = 0) followed by 800 µg naloxone i.v. (n = 8) or placebo (n = 8) at t = 120 min. At the 
following times steady-state ventilation was measured (measurement period 7 min): -10 min 
(ten min prior to drug infusion), 15, 75, 140, 180, 240, 300, 360, 420 and 480 min after drug 
infusion. t-Tests were performed to detect a significant effect of naloxone on ventilation at the 
P < 0.05 level. 
 
Study 2  
Twenty-four subjects participated in this study. All received 0.1 mg buprenorphine i.v. at 
t = 2 min, followed by a continuous infusion for 1 h of 0.1 mg.h-1 (total dose = 0.2 mg in 
60 min). At t = 32 min, x mg naloxone i.v. was given followed by a continuous infusion for 
30-min of 2·x.h-1 (total dose = 2·x mg in 30 min). The following values of 2·x were tested: 
0 (placebo), 0.5, 1, 2, 3, 4, 5, 6 and 7 mg. Each dose was tested in two subjects, except for 
placebo that was tested in eight subjects. Breathing was measured continuously from 2 min 
prior to buprenorphine infusion until 90 min after the start of infusion.  
 
The breath-to-breath data were averaged over 1-min periods. An ensemble average was 
performed on the data of the eight subjects receiving the buprenorphine/placebo combination, 
allowing the calculation of buprenorphine/placebo-induced respiratory effect at various times. 
To quantify the respiratory effect of naloxone relative to placebo we used the following 
formula on the data of each subject that had received the buprenorphine–naloxone 
combination: 
 
Reversal(z) =  [Vi, naloxone(z)  – Vi, placebo(z)] / [Vi, baseline – Vi, placebo(z)] 
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where period z ranges from t = 61 to t = 63 min (i.e., 1 min before to 1 min after the end of the 
continuous naloxone infusion); Vi, placebo(z) is mean minute ventilation in the placebo during 
period z, Vi, naloxone(z) mean ventilation of the equivalent period after naloxone, and Vi, baseline 
mean ventilation of the 2 min prior to the buprenorphine infusion. This analysis will yield a 
quantitative measure of reversal with 0 indicating no reversal (naloxone no better than 
placebo) and 1 full reversal (response returned to pre-buprenorphine level).  
 
In order to get an impression of the naloxone dose-effect relationship on this 0.2 mg 
buprenorphine-induced respiratory depression, we fitted the dose-reversal data using the 
following sigmoid Emax function incorporating an inhibitory component (using NONMEM): 
 
Reversal = (dose/D1)γ / (1 + (dose/D1)γ) · [1/(1 + (dose/D2)γ)] 
 
where D1 and D2 are the naloxone doses causing 50% reversal and return to 50% depression, 
respectively, and γ a shape parameter. 
 
Study 3  
Thirty-two subjects participated in this study.  
STUDY 3.1: Sixteen received 0.1 mg buprenorphine i.v. at t = 2 min, followed by a 
continuous infusion for 1 h of 0.1 mg.h-1 (total dose = 0.2 mg in 60 min). At t = 32 min, 2 mg 
naloxone (n = 8) or placebo (n = 8) was infused, followed by an infusion of 4 mg.h-1 for 2 h.  
 
STUDY 3.2: Sixteen other subjects received 0.2 mg buprenorphine i.v. at t = 2 min, followed 
by a continuous infusion for 1 h of 0.2 mg.h-1 (total dose = 0.4 mg in 60 min). At t = 32 min, 
3 mg naloxone (n = 8) or placebo (n = 8) was infused, followed by a continuous infusion of 
4 mg.h-1 for 2 h. The bolus naloxone dose was 50% greater than that of Study 3.1. This was 
based on a pilot study in 3 subjects that showed the need for a greater initial dose of naloxone 
after 0.4 mg buprenorphine compared to 0.2 mg buprenorphine. 
 
Ventilation was initially measured continuously from 2 min prior to buprenorphine infusion 
until 120 min after the start of infusion. Subsequently measurements were made at 30-min 
intervals until t = 240 min, after which hourly measurements were performed until 
t = 420 min. 
 
The breath-to-breath data were averaged over 1-min periods. An ensemble average was 
performed on the naloxone and placebo data groups. The values were compared to baseline 
ventilation (± its 95% confidence interval).10 When the mean ventilation value equalled or 
crossed [baseline ventilation – 1×95% confidence interval], we somewhat arbitrarily assumed 
that ventilation had returned to pre-drug baseline. 
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Study 4 
Sixteen subjects participated in this study. All received 0.15 mg.kg-1 morphine i.v. at t = 0. 
Eight subjects received 400 µg naloxone i.v. at t = 30 min; eight others received placebo at 
t = 30 min. Ventilation was initially measured continuously from t = 0 until t = 90 min. 
Subsequently measurements were obtained at 30-min intervals until t = 240 min. The breath-
to-breath data were averaged over 1-min periods. Next ensemble averages were obtained and 
the data was compared to baseline ventilation in a similar fashion as in Study 3. 
 
Study 5 
Eight subjects received alfentanil i.v. by Target Controlled Infusion (TCI) using a palm-top 
computer (Psion 3C, London, UK) programmed with the population pharmacokinetic data set 
of Maitre et al. In this study we used a target plasma alfentanil concentration of 30 ng.ml-1. 
This concentration was used previously to reduce the hypoxic ventilatory response by 50%. 
Before the alfentanil infusion and 15 min after a ‘steady-state’ concentration was obtained, we 
obtained a hypoxic ventilatory response, after which naloxone, 4 µg.kg-1 i.v. (280 µg in a 
70 kg person), was administered and 15 min later the third and last hypoxic response was 
obtained. Ten-breath averages were used in the data analysis. The hypoxic sensitivity was 
calculated by dividing the change in ventilation from normoxia to hypoxia by the change in 
arterial hemoglobin-oxygen saturation:11 
 
Hypoxic sensitivity = [Vi, hypoxia – Vi, normoxia] / [SpO2, normoxia – SpO2, hypoxia] 
 
(data points derived from the last ten breaths prior to hypoxia and the last ten breaths of 
hypoxia). Statistical analysis was by one-way analysis of variance with post-hoc t-test. 





All subjects completed the studies without major side effects. The most frequent side effect 
was nausea and vomiting which occurred in 70% after buprenorphine, 50% after morphine 
and 0% after alfentanil. 
 
Study 1 
The averaged responses of the naloxone (800 µg) and placebo administration following 
0.2 mg buprenorphine are shown in figure 1. At none of the measurement times did these two 
groups differ in the change in ventilation (or absolute ventilation values, data not shown). In 
order to detect a small effect of naloxone on ventilation unobserved in the averaged data, we 
calculated the difference in ventilation from t = 75 to t = 180 min. In the placebo group the 
change in ventilation was 0.2 ± 0.5 l.min-1 against 2.2 ± 0.7 l.min-1 in the naloxone group. 
This difference did not reach the level of significance (P = 0.08, one-tailed t-test, assuming a 
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larger response in the naloxone group). Our data indicate that the buprenorphine effect on 



























Figure 1. Influence of 800 µg naloxone on 0.2 mg buprenorphine-induced change in 
ventilation (∆ventilation).  Buprenorphine was given at time t = 0 min; naloxone or 
placebo at time t = 120 min.  Square is predrug baseline value (0 l.min-1). Closed 




The mean effect of buprenorphine/placebo on minute ventilation is given in figure 2 (grey 
area). Baseline ventilation was 24.0 ± 3.3 l.min-1 at a fixed PETCO2 of 7.0 ± 0.1 kPa. Peak 
depression of ventilation occurred at t = 71 min after the start of the buprenorphine infusion 
reaching a value of 13.5 ± 1.5 l.min-1. Relative to baseline, peak depression was 62 ± 11%, 
indicating a reduction of baseline ventilation by 38%. In order to get an impression of the 
naloxone data, we plotted the data of two subjects given 2 and 6 mg naloxone in figure 2. The 
subject receiving 2 mg showed full reversal back to baseline (reversal = 1). In contrast, the 
subject given the higher naloxone dose showed little reversal (reversal = 0.1). In figure 3 we 
plotted the individual dose–reversal data for the time frame 61–63 min. The data show that 
full reversal ± 20% was obtained at doses between 2 and 4 mg naloxone, but that at higher 
doses reversal gradually declined. We calculated the naloxone dose causing 50% reversal of 
0.95 ± 0.09 mg and the naloxone dose causing the return to 50% depression of 5.2 ± 0.22 mg 
(data fitted to a sigmoid Emax model with inhibitory component, see methods; values are 
median ± SE). 

















Baseline ventilation averaged to 21.9 ± 2.5 l.min-1 (data from studies 3.1 and 3.2 combined). 
The effect of both doses of buprenorphine (0.2 and 0.4 mg) were successfully reversed by a 
continuous infusion of naloxone at the dose chosen by us, which was, at least partly, based on 
the data from Study 2. 
 
STUDY 3.1. See figure 4. Buprenorphine, 0.2 mg, caused a rapid decrease in ventilation. 
Prior to naloxone or placebo infusion (t = 32 min), ventilation was 84 ± 3% and 79 ± 5% of 
baseline, respectively. In the placebo group, ventilation declined further to a nadir of 57 ± 6% 
of baseline at t = 120 min. In the naloxone group, the nadir was 78 ± 4% of baseline at t = 
48 min (at the same time ventilation was 61 ± 5% of baseline in the placebo group). From that 
point on ventilation increased to reach baseline values (that is baseline ventilation – 1×95% 
confidence interval) at t = 70 min. Ventilation remained not different from baseline during the 
remainder of the naloxone infusion. After termination of the naloxone infusion (at t = 
152 min) ventilation decreased but it never reached the level observed in the placebo group. 
 
STUDY 3.2. See figure 4. A rapid decrease in ventilation occurred after the initiation of the 
0.4 mg buprenorphine infusion. Prior to naloxone or placebo infusion (t = 32 min), ventilation 
Naloxone dose (mg per 70 kg)









































Buprenorphine    Naloxone / Placebo
Figure 2. Buprenorphine (0.2 mg given over 
60 min) induced respiratory depression.  
Grey area is the mean ± SEM of the combination 
of buprenorphine and placebo (n = 8). The 
individual data (1-min averages) of two subjects 
receiving the combination of buprenorphine and 
naloxone are superimposed. Open circles: subject 
receiving 2 mg naloxone, closed circles: subject 
receiving 6 mg naloxone. Naloxone or placebo 
was given over 30 min.  
Figure 3. Influence of placebo and 0.5 to 7 mg 
naloxone reversal on 0.2 mg buprenorphine-
induced respiratory depression. Reversal ranges 
from 0 (no reversal) to 1 (complete reversal). 
Circles are values of individual subjects (two 
subjects received 0.5 mg naloxone; 8 subjects 
placebo). Grey field indicates the area of full 
reversal ± 20%. The line through the data is the fit 



























was 62 ± 5% and 64 ± 5% of baseline, respectively. In the placebo group, ventilation declined 
further to a nadir of 40 ± 3% of baseline at t = 150 min. In the naloxone group, the ventilation 
nadir was 61 ± 5% of baseline at t = 34 min (ventilation of the placebo group was 66 ± 7% at 
t = 34 min). From that point on ventilation increased to reach baseline values at t = 93 min. 
Ventilation remained not different from baseline during the remainder of the naloxone 
infusion. After termination of the naloxone or placebo infusion (at t = 152 min) the changes in 





Figure 4. Influence of a continuous infusion of naloxone and placebo on 0.2 mg buprenorphine- (left) 
and 0.4 mg buprenorphine-induced respiratory depression (right). The buprenorphine dose was given 
over 60 min from t = 2 to t = 62 min. Naloxone or placebo was given for 2 h, from t = 32 to                  
t = 152 min. Closed circles: naloxone (n = 8); open circles: placebo (n = 8). The grey area represents 




See figure 5. Morphine, 0.15 mg.kg-1, caused a rapid decrease in ventilation (baseline = 
20.4 ± 1.0 l.min-1). Prior to infusion of naloxone and placebo, ventilation was reduced to 
14.1 ± 0.6 and 12.4 ± 1.5 l.min-1 in the naloxone and placebo groups, respectively. While 
placebo had little effect on ventilation, 400 µg naloxone caused a rapid return of ventilation to 
baseline. Ventilation was not different from baseline from t = 37 to t = 66 min, after which it 
gradually returned towards placebo-levels. 
 
Study 5 
The predrug hypoxic sensitivity was 1.22 ± 0.21 l.min-1.%-1. Alfentanil caused the severe 
impairment of the hypoxic sensitivity (reduction > 50% to 0.48 ± 0.35 l.min-1.%-1; P < 0.05 
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versus predrug control and naloxone) which was fully restored by 4 µg.kg-1 naloxone 






























Figure 5. Influence of 400 µg naloxone or placebo (given at t = 30 min) on 0.15 mg.kg-1 morphine-
induced respiratory depression. Open circles are naloxone data (n = 8); closed circles placebo (n = 8). 





In our studies, we observed that, while 0.4 mg i.v. naloxone (given in 90 s) caused full 
reversal of morphine- and alfentanil-induced respiratory depression (both are full µ-opioid 
receptor agonists), a double dose of naloxone (0.8 mg) had no effect on respiratory depression 
induced by the opioid analgesic buprenorphine. We next explored the naloxone dose–
response relationship and observed that increasing doses of naloxone caused full reversal of 
0.2 mg buprenorphine-induced respiratory depression (2–4 mg naloxone given in 30 min). 
Further increasing the naloxone dose (5–7 mg), however, caused a decline in reversal activity. 
The form of the dose–response relationship is best described by a bell-shape or inverse U. 
Taken into account these data, we designed a naloxone infusion scheme intended to cause full 
reversal of the respiratory depression from 0.2 and 0.4 mg buprenorphine. A naloxone bolus 


















40 to 60 min. Renarcotization did occur upon the termination of the naloxone infusion. These 
data indicate that reversal of buprenorphine-induced respiratory depression is only possible (i) 
with a continuous infusion of naloxone and (ii) with a specific naloxone dose chosen based on 
the buprenorphine dose and the form of the naloxone dose–response curve.  
 
All opioids that interact with the µ-opioid receptor system depress respiration.12 
Buprenorphine is no exception to that rule. The extent of respiratory effect is highly variable 
and is related to the specific opioid, the opioid dose, the administration mode, concurrent 
medication, underlying disease, pain and the state of arousal (these two factors vary over 
time), genetics and exogenous stimulatory factors. Since the occurrence of overt and 
sometimes life-threatening respiratory depression is often unpredictable, the ability to induce 
rapid opioid reversal is of evident importance. In contemporary medicine, naloxone has 
become the drug of choice for treatment of opioid-induced respiratory depression. Naloxone 
is a non-specific opioid receptor antagonist (i.e., it antagonizes the µ-, κ- and δ-opioid 
receptor) with a relatively short duration of action resulting from rapid elimination; its half-
life in plasma is about 30–45 min.13  
 
Although there is ample evidence that buprenorphine, just like other µ-opioid receptor 
agonists, produces significant respiratory depression at clinical doses (see figures 1, 2 and 4), 
sparse data from the literature addressed the issue of reversal of buprenorphine-induced 
respiratory depression.5-7 The picture that emerges from these few studies is that at relatively 
large bolus naloxone doses little (that is, just partial) reversal of buprenorphine's respiratory 
effects is observed. For example a recent short report indicated that an incremental naloxone 
dose of 2.4 mg has an effect on 0.4 mg buprenorphine-induced respiratory depression no 
greater than placebo in patients during sevoflurane/nitrous oxide anesthesia.7 An older study 
by Gal showed only partial reversal of 0.3 mg buprenorphine-induced respiratory depression 
with 5 and 10 mg i.v. naloxone (given as single bolus).5 The inability to obtain full reversal in 
these two studies may be related to various factors, such as: anesthesia (anesthesia must be 
considered a serious complication when studying opioid-induced respiratory depression due 
to the complex opioid–anesthetic interaction on breathing),14,15 the lack of sensitivity of the 
respiratory model applied to assess naloxone–buprenorphine interaction, the use of single 
naloxone doses and finally the use of a too high dose of naloxone (see figure 3). 
 
The resistance to naloxone reversal is related to the very high affinity of buprenorphine for 
the µ-opioid receptor.13 This very high affinity explains why relatively high doses of naloxone 
(2–4 mg) are needed before complete reversal is observed. The need for a continuous infusion 
in this process (upon termination of the naloxone infusion there was a rapid return of 
respiratory depression, see figure 4) implies the need for continuous supply of naloxone to the 
opioid receptor sites in the brain involved in respiratory depression. Otherwise the naloxone 
bolus is rapidly washed out from the brain compartment and eliminated from the body. We 
believe that the use of a single dose naloxone infusion to reverse opioid-related overdose has 
several disadvantages which are unrelated to the opioid involved: renarcotization due to 
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naloxone’s short duration of action (in case of morphine see figure 5), the inability to titrate to 
effect causing the return of pain and sympathico-excitation. An infusion regimen aimed at a 
prolonged and steady-state naloxone plasma concentration may overcome these shortcomings. 
For example, continuous (11 h) naloxone infusion after high-dose fentanyl anesthesia caused 
reversal of respiratory depression without causing renarcotization, pain, or sympathico-
excitation.16 
 
An interesting observation in Studies 3.1 and 3.2 is the higher ventilation levels after 
naloxone treatment than after placebo treatment at times when naloxone is washed out from 
the brain and possibly also from the body (see figure 4 at t > 240 min). This is probably due to 
washout from the brain compartment of buprenorphine that was replaced by naloxone at the 
µ-opioid receptor or at non-specific binding sites (i.e., some buprenorphine was lost without 
replacement). A similar observation was not made for morphine (figure 5). This may suggest 
that the morphine, which accumulates at intracellular sites in the brain,17 fully replaces the 
morphine which was washed-out after naloxone-replacement at the receptor.  
 
Naloxone doses exceeding the maximal effective dose (> 4 mg) lead to a decrease in (0.2 mg) 
buprenorphine reversal efficacy (figure 3). Since the number of subjects was limited (just 
2 subjects per naloxone dose over the dose range from 0.5–7 mg) we consider this observation 
preliminary. Evidently, further studies are needed. In a first attempt, we performed a set of 
experiments after 0.4 mg buprenorphine and applied various naloxone doses (1 dose per 
subject; duration of naloxone infusion 30 min) and observed a similar bell-shaped dose–
response relationship albeit full reversal was not reached (Dahan, unpublished observation). 
Our unexpected observation may be specific to the naloxone molecule or to buprenorphine 
and its interaction with naloxone. If it is just a naloxone effect, our data suggest that naloxone 
turns from a full antagonist to an agonist at high dose. We are unaware of any studies on 
increasing doses of naloxone on opioid-analgesia or opioid-side effects. Buprenorphine per se 
has a long history of showing bell-shaped dose–response curves with respect to its analgesic 
and side effect profile.1,18 Most of these observations were made in animals. For example, 
rodents display a bell-shape buprenorphine dose–response relationship in various 
antinociceptive assays (electrical pain, heat pain, visceral pain and spinal nerve ligation) and 
on respiratory depression (using arterial PCO2 as end point).19-21 Also in humans there are 
indications of the existence of a bell-shaped dose–response curve with respect to analgesia. 
For example, two patients treated with buprenorphine (30–40 µg.kg-1) for postoperative pain 
showed improved pain relief after 0.4 mg naloxone infusion, probably due to shifting of the 
bell-shaped dose–analgesia curve to the right.22 A rightward-shift of the bell-shaped 
buprenorphine dose–response curve after the infusion of an opioid-antagonist (naltrexone) has 
been observed in rats using an electrical pain test.19 Note that a bell-shaped curve was actually 
never observed in experimental human studies and clinically complete analgesia is reached 
with buprenorphine. The mechanism of the bell-shape curve remains unknown. Some argued 
that the form of the curve is related to the type and intensity of (experimental) pain 
administered.21 Others suggested non-competitive autoinhibition, in which there are two 
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receptor subpopulations, one mediating the agonistic properties at low dose, the other 
mediating the antagonistic properties at high dose.3,19,21,23 Finally, Lutfy et al.24 suggest the 
contribution of the ORL1 receptor. They showed that buprenorphine, but not morphine, given 
to mice activates ORL1 receptors, compromising (antagonizing) analgesia from µ-opioid 
receptors. The latter theory seems not plausible taken into account that the scanty literature 
which exists on the respiratory effects of stimulation of ORL1 receptors shows respiratory 
depression rather than stimulation.25 The existence of two µ-opioid receptor subpopulations as 
described above could also theoretically explain our findings with high-dose naloxone 
causing the antagonism of the receptors mediating the antagonistic effects of buprenorphine. 
We are not aware, however, of any observation of these two receptor subpopulations in in 
vitro or in vivo animal studies. 
 
We studied respiration in a group of healthy young volunteers and not in patients of various 
ages with pain. Hence, we remain uninformed what the effect of the naloxone–buprenorphine 
interaction is on pain and respiration in acute and chronic pain patients. Clinical studies in 
patients on buprenorphine treatment will be necessary to elucidate these important matters. 
 
Finally, studying the ability to reverse opioid-induced side effects is not only relevant to 
compounds with high affinity for the µ-opioid receptor, such as buprenorphine. Since only 
few studies addressed the issue of long-term opioid reversal, we believe that more studies are 
required to assess –in case of respiratory depression– the specific dose and administration 
mode of naloxone needed to restore breathing and maintain it at an adequate level. This is 
relevant to opioids given at high dose, long acting opioids and opioids given as a continuous 
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Respiratory Effects of Carbonic Anhydrase 






5 Antioxidants Reverse Depression of the Hypoxic Ventilatory 
Response by Acetazolamide in Man 
 
 
A major defense of the mammalian body to acute hypoxia is a rapid increase in pulmonary 
ventilation called the acute hypoxic response (AHR). This vital chemoreflex is primarily 
mediated by the carotid bodies located at the bifurcations of the common carotid arteries.1 A 
decrease in oxygen tension in the blood leads to a complex cascade of events in carotid body 
type I cells, in which closure of one or more classes of potassium channels results in 
membrane depolarization.2-4 The mechanistic link between hypoxia and potassium channel 
closure is unknown; however, potassium channels are sensitive to oxidizing and reducing 
agents, and reactive oxygen species (ROS).5,6 Whether ROS indeed play a mediating role in 
oxygen sensing is controversial.7 Recently, Hildebrandt et al. have shown that after a 5-day 
oral application, N-acetylcysteine increased the hypoxic response in young adults indicating a 
possible specific involvement of gluthathione in oxygen sensing.8 In older women with an 
age-related reduction of hypoxic sensitivity, ascorbic acid supplementation appeared to 
increase their hypoxic response.9 Recently, we showed that an antioxidant mixture, consisting 
of oral α-tocopherol and intravenous ascorbic acid was able to reverse the reduction of the 
hypoxic response in humans by subanesthetic concentrations of inhalational anesthetics.10,11 
These studies indicate that antioxidants may be able to increase carotid body sensitivity in a 
situation wherein their output is reduced. If this is a general property of antioxidants remains 
to be seen, and in this context it would be of interest to investigate whether they would also be 
able to reverse carotid body inhibition that is induced by other means than anesthetics or age-
related phenomena. One other, pharmacological, means to reduce carotid body sensitivity is 
acetazolamide, a well-known carbonic anhydrase inhibitor. The mechanism by which 
acetazolamide reduces the hypoxic response in man12 and animals13,14 is unclear, but could 
involve opening of potassium channels15 and/or inhibition of one or more carbonic anhydrase 
iso-enzymes that have been shown to be present in the carotid bodies,16 and at least one of 
which appears to act as a scavenger of reactive oxygen species in cultured cells.17 Previous 
studies have shown that the effect of acetazolamide on the hypoxic response strongly depends 
on the dose and route of administration.12-14 The aims of the present study in healthy 
volunteers were twofold. First, we wished to examine if an intravenous acetazolamide dose as 
low as 4 mg.kg-1 would reduce the carotid body-mediated acute hypoxic response in man. 
Second, we wished to examine if a reduction of the acute hypoxic response by acetazolamide 
could be reversed by antioxidants (1 g ascorbic acid i.v. and 200 mg α-tocopherol p.o.), 
suggesting a modulating role of the redox status of blood in oxygen sensing or a potential role 






Sixteen volunteers (8 men, 8 women, equally distributed over two subject groups, age        
19–24 years; all of them gave informed consent) participated in the study after approval from 
the local Human Ethics Committee. All experiments conformed to the Declaration of 
Helsinki. All subjects were healthy, did not smoke or use any illicit drugs. They underwent a 
series of test experiments to familiarize them with the apparatus and experimental procedures. 
The subjects were instructed not to eat or drink for at least 8 hours prior to the study. After 
arrival in the laboratory, a catheter was inserted into the right antecubital vein for drug 
infusion and into the left radial artery for arterial blood gas analysis (ABL 700 Radiometer 
Copenhagen, Brønshøj, Denmark).  
 
Respiration 
The subjects breathed through a face mask, which was connected to a gas mixing system 
which received oxygen, carbon dioxide and nitrogen from three mass flow controllers. Gas 
flow was measured with a pneumotachograph (Fleisch, Lausanne, Switzerland) connected to 
a pressure transducer and electronically integrated to yield a volume signal.  This signal was 
calibrated with a motor-driven piston pump (stroke volume 1000 ml, frequency 20 min-1). 
Corrections were made for the changes in gas viscosity due to changes in oxygen 
concentration of the inhaled gas mixtures. The pneumotachograph was connected to a 
T-piece.  One arm of the T-piece received a gas mixture (with a flow of 50 l.min-1) from a gas 
mixing system consisting of three mass flow controllers (Bronkhorst High-Tech BV, 
Veenendaal, The Netherlands). A personal computer provided control signals to the mass 
flow controllers so that the composition of the inspired gas mixtures could be adjusted to 
force end-tidal oxygen concentration (PETO2) to follow a specified pattern in time while the 
end-tidal carbon dioxide concentration (PETCO2) was kept constant.18,19 The oxygen and 
carbon dioxide concentrations of inspired and expired gases were measured with a gas 
monitor (Multicap, Datex-Engstrom, Helsinki, Finland) by paramagnetic and infrared 
analysis.  The gas monitor was calibrated with gas mixtures of known composition delivered 
by a gas-mixing pump (Wösthoff, Bochum, Germany). The arterial hemoglobin-O2 saturation 
obtained via a finger probe (SpO2) was measured by pulse oximetry (Sattelite Plus, Datex-
Engstrom). Respiratory parameters were collected on a breath-to-breath basis and stored on 
disc for further analysis. 
 
Study Design and Data Analysis 
Subjects were randomly divided into two groups and exposed to three treatments: control 
(CON) followed by acetazolamide (AZ) and antioxidants for the antioxidants (AOX) group 
and control (CON) followed by acetazolamide (AZ) and placebo for the placebo (PLCB) 
group. In both groups, two hypoxic exposures were applied during each of the three 
treatments, one at a constant normocapnic end-tidal PCO2 (PETCO2, ‘normocapnic 
experiments’ in table 2, resulting in normocapnic clamped levels of ventilation), and one at a 
constant hypercapnic PETCO2 (‘hypercapnic experiments’ in table 2, resulting in hypercapnic 
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clamped levels of ventilation). The order of these CO2 levels was random. Hypoxia was 
induced with dynamic end-tidal forcing by which steps from normoxia (PETO2 15 kPa) into 
hypoxia (PETO2 6.2 kPa, obtained within 4 to 6 breaths) were applied.11,14,18,19 Since peak 
hypoxic ventilatory responses occur within three min,19 hypoxia was maintained for three 
min, after which hyperoxia was introduced for 5 min (FiO2 > 0.5).  Subsequently, the PETO2 
sequence was repeated at the alternate PETCO2 level. 
 
In all subjects control hypoxic studies at both CO2 levels (no drugs given) were followed by 
the intravenous administration of 4 mg.kg-1 acetazolamide (AHP Pharma SA, France). 
Twenty minutes after the AZ infusion, a second set of hypoxic studies was performed at both 
PETCO2 levels. Next, eight subjects received the antioxidant cocktail (AOX group), eight 
others placebo (PLCB group). The antioxidant mixture consisted of 200 mg α-tocopherol 
(dl-α-tocoferolacetaat, OPG Farma, Utrecht, The Netherlands) ingested with a cup of yoghurt 
and 1 gram ascorbic acid (Ascorbinezuur CF, Centrafarm, Etten-Leur, The Netherlands), 
infused intravenously 35 min after the α-tocopherol application. The placebo mixture 
(manufactured by the local pharmacy) consisted of cellulose tablets (ingested with yoghurt), 
and saline, infused 35 min after the ingestion of cellulose. The final sets of hypoxic studies 
were performed 10 min after the infusions of AOX and saline in the AOX and PLCB groups, 
respectively. With respect to the administration of the antioxidants and placebo, the study had 
a double blind, randomized design.  
 
The breath-to-breath data of the last 10 breaths of normoxia (prior to hypoxia) and of hypoxia 
(prior to hyperoxia) were averaged. Hypoxic ventilatory sensitivity (or acute hypoxic 
ventilatory response, AHR; units l.min-1. %-1) was calculated as:18  
 
AHR = [Vi, hypoxia – Vi, normoxia] / [SpO2, normoxia – SpO2, hypoxia] 
 
The statistical analysis was performed using SPSS v11.0 for Windows (SPSS Inc., Chicago, 
IL, USA, 2003). A two-way repeated measures analysis of variance with post-hoc Bonferroni 
correction was performed to detect significant differences among the three treatment levels 
within the AOX group (CON – AZ – AOX) and the PLCB group (CON – AZ – PCLB). 
P-values < 0.05 were considered significant. Unless otherwise indicated, values are reported 





All subjects completed the sessions without side effects, except one subject belonging to the 
PLCB group who withdrew after one session for unknown reasons.  
 
The effects of acetazolamide on resting arterial acid–base and [K+] are shown in table 1. In 
both groups of volunteers, the agent induced small reductions in mean potassium and 
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bicarbonate concentrations and base excess. No significant differences in mean resting minute 
ventilation and PETCO2 were observed between control and AZ or AZ + AOX in the AOX 
group and control and AZ or AZ + PLCB in the PLCB group (table 2). After acetazolamide 
administration, there was no detectable increase in the arterial-to-end-tidal PCO2 (P(a–ET)CO2) 
gradient indicating incomplete erythrocytic carbonic anhydrase inhibition. We observed no 
effect of low intravenous dose acetazolamide on arterial blood pressure (data not shown).  
 
 
Table 1. Effects of acetazolamide on blood acid–base status. 
 
Antioxidant group (n = 8) Control Acetazolamide 
PaCO2 (kPa) 5.6 ± 0.3 5.4 ± 0.4  
P(a–ET)CO2 (kPa) 0.00 ± 0.15  -0.08 ± 0.24  
Arterial pH 7.39 ± 0.01  7.37 ± 0.01 † 
Arterial [bicarbonate] (mM) 24.8 ± 1.4  22.7 ± 1.6 † 
Base excess (mM) -0.3 ± 1.1  -2.5 ± 1.2 † 
Arterial [K+] (mM) 4.1 ± 0.3  3.9 ± 0.3 § 
SpO2 (%) 97.6 ± 0.4  96.8 ± 1.1 * 
Placebo group (n = 7)   
PaCO2 (kPa) 5.4 ± 0.5  5.2 ± 0.4  
P(a–ET)CO2 (kPa) 0.04 ± 0.26  -0.09 ± 0.33  
Arterial pH 7.38 ± 0.03  7.37 ± 0.02 * 
Arterial [bicarbonate] (mM) 24.1 ± 1.8  21.9 ± 1.6 ‡ 
Base excess (mM) -0.9 ± 1.6  -3.0 ± 1.2 † 
Arterial [K+] (mM) 4.1 ± 0.2  3.7 ± 0.3 † 
SpO2 (%) 97.6 ± 0.2  97.7 ± 0.4  
 
Effect of acetazolamide on resting blood gas and electrolyte parameters in eupneic resting conditions. 
Data are given as mean ± SD. * P < 0.05;  † P < 0.01; ‡ P < 0.02;  § P < 0.03. Blood gas analysis was 
performed to check for possible P(a–ET)CO2 differences following acetazolamide infusion. 
 
 
Normocapnic clamped PETCO2 values were 5.9 ± 0.1 and 5.7 ± 0.2 kPa in the AOX and 
PLCB group, respectively. In both subject groups, the clamped PETCO2 was increased by 
0.5 kPa to perform a hypercapnic AHR. When going from the normocapnic to the 
hypercapnic PETCO2, both subject groups showed an about equal increase in AHR (O2–CO2 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The effects of AZ, AOX and PLCB on the mean AHR in both subject groups are summarized 
in table 2 and graphically presented in figure 1. The effects of AZ, AOX and PLCB on the 
normocapnic AHR of one individual is presented in figure 2. The mean normocapnic AHR’s 
were reduced by 37% and 33% in the AOX and PLCB groups, respectively (not significantly 
different between the two groups, table 2). This inhibiting effect on the hypercapnic AHR was 
even larger (52% and 47% reduction in the AOX and PLCB groups, respectively, not 
significantly different between the two groups): in fact, AZ abolished any O2–CO2 interaction 
(figure 1, table 2). In the subjects of the AOX group that showed a reduced normocapnic and 
hypercapnic AHR upon AZ, this effect was reversed by AOX. In normocapnia, this reversal 
was total, while in hypercapnia a complete or almost complete reversal occurred in all 
individuals except one in which it was partial (for mean data see table 2). After AOX, all 
these individuals showed a larger hypercapnic than normocapnic AHR indicating a reversal of 
the O2–CO2 interaction. Note that both the normocapnic and hypercapnic AHR’s after 
AZ + AOX did not significantly differ from those during control. 
 
In contrast to the subjects receiving AOX, those receiving placebo did not show reversal of 
the acetazolamide-induced inhibition of the normocapnic and hypercapnic AHR. At both 
PETCO2 levels, the AHR after AZ + PLCB was not different from that after AZ alone. After 
Figure 1. Effects of antioxidants (left panel) and placebo (right panel) on acetazolamide-induced 
inhibition of normocapnic (N) and hypercapnic (H) hypoxic responses. Control data are shown at 
left in both panels. Note the increase in hypoxic sensitivity when going from normocapnia to 
hypercapnia (O2–CO2 interaction) in control studies that is abolished after acetazolamide (shown in 
the middle of both panels). The left panel shows that after antioxidant administration, the 
normocapnic hypoxic response is fully restored, while the O2–CO2 interaction reappears. After 
placebo (right panel), the normocapnic and hypercapnic hypoxic responses clearly remain below 
control and no O2–CO2 interaction reappears. Paired t-test: + P < 0.001; ++ P = 0.02. 
Control – Acetazol ide – A ti xidants         Co t l – Acet lamide – lacebo 
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AZ + PLCB, some subjects in this group showed a somewhat larger, and others an equal or 
somewhat smaller hypercapnic than normocapnic AHR so that in contrast to those treated 




    
 
Figure 2. Effects of antioxidants (top) and placebo (bottom) on the acetazolamide-induced depression of 
the normocapnic acute hypoxic ventilatory response of one individual. Antioxidants reverse the depression 
but placebo fails to do so. Ventilatory data are show breath-by-breath. 
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In this study in healthy volunteers, acetazolamide (4 mg.kg-1 i.v.) reduced the normocapnic 
and hypercapnic hypoxic response by about 35% and 50%, respectively, and prevented the 
increase in hypoxic response that normally occurs with a rise in arterial PCO2 (O2–CO2 
interaction; note also that the inhibiting effect of acetazolamide occurred despite a small 
significant decrease in arterial pH that normally would tend to increase the AHR). A mixture 
of antioxidants (200 mg α-tocopherol p.o. and 1 g ascorbic acid i.v.) reversed these inhibiting 
effects of acetazolamide on the hypoxic response.  
 
 
Methodology and Study Design: General Considerations 
Two issues that should be discussed concern the acetazolamide dose and the timing of the 
ventilatory measurements. The acetazolamide dose that is needed to obtain an acute maximal 
physiological effect from carotid body carbonic anhydrase inhibition has not been 
systematically explored. For most organs it is 5–10 mg.kg-1, but for kidneys, containing an 
enzyme concentration similar to carotid bodies, it is smaller.20,21 From available human data,22 
we estimate a free unbound (diffusible) drug concentration in our subjects of about 8 µM at 
the beginning of the elimination phase which is insufficient for impairment of red cell 
function,20,21 but well within a concentration range necessary for lowering intraocular pressure 
(EC50 ~7 µM).23 The concentration needed for maximal inhibition of carotid body function 
probably lies between 8 and 15 µM, because already at 12–15 µM the hypoxic response is 
abolished.12 In order to reach this concentration of ~15 µM, we considered initially to 
administer 500 mg to our subjects, because this could have told us whether the hypoxic 
response after AOX would reappear after its abolishment by acetazolamide. However, this 
could have the disadvantage of studying an effect that could be confounded by sufficient 
erythrocytic CA inhibition to result in tissue acidosis21 and the inability to perform real 
isocapnic measurements (note the absence of a P(a–ET)CO2 gradient after acetazolamide 
infusion, see table 1).24 Nevertheless, together with those of Swenson and Hughes12, our data 
indicate a strong dose-dependent effect of acetazolamide on carotid body function in a narrow 
concentration range. 
 
The time course of the effect of intravenous acetazolamide on the control of breathing is not 
well described. In the anesthetized cat, an intravenous dose of 4 mg.kg-1 abolishes the        
O2–CO2 interaction and reduces hypoxic sensitivity by half, effects that are still demonstrable 
about 100 min after infusion.14,24 Similar to Swenson and Hughes,12 we performed the 
ventilatory measurements within one elimination half time of acetazolamide which after an 
intravenous bolus is ~1.7 h.22,25 The estimated prevailing plasma concentration (~5 µM) at the 
time of the last ventilatory measurements (AHR after AZ + AOX/PLCB) is well within the 
range reported to cause physiological effects in various peripheral tissues except 
erythrocytes.20-23 A long-lasting inhibition of carotid body function by acetazolamide was 
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confirmed in our subjects receiving AZ + PLCB because on average they still showed a 
hypoxic response that was significantly lower than control. 
 
 
Reduction of the AHR by Acetazolamide and Reversal by AOX 
Our observations are from intact organisms and this compels us to be cautious with 
extrapolating them back to processes occurring at the cellular level. However, available data 
obtained from reduced preparations may help us to place our observations into a proper 
context. For the sake of brevity, we will only discuss two scenarios that may be helpful to 
explain our findings. 
 
Scenario 1. Inhibition of the AHR by acetazolamide is due to inhibition of a carbonic 
anhydrase (CA) isoform. It is assumed that the antioxidants that we administered did not 
influence acetazolamide’s binding to the isoenzyme but rather exerted an independent 
reducing effect, for example by scavenging ROS.26,27 Because AOX reversed an inhibitory 
effect of a carbonic anhydrase inhibitor, we consider a possible role of some CA isoforms as a 
ROS scavenger. Two candidates for such an antioxidant function could be CA III and IV, the 
latter because it contains cysteine groups that may participate in redox reactions,28 and the 
former because it behaves as an important ROS scavenger17 and is present in type I carotid 
body cells from rat.16 CA III is a cytoplasmic enzyme with a relatively low affinity for 
sulfonamide inhibitors,29 while at the same time acetazolamide is only moderately 
permeable.30 These two factors, acetazolamide’s limited permeability and its low affinity for 
CA III could then explain why a relatively high dose is needed to completely abolish the 
hypoxic ventilatory response.13 With regard to CA IV, we are not aware of data showing a 
role of this protein in regulating the (extracellular) redox state, for example by 
S-glutathiolation of one or more of its cysteine residues.28 It should also be mentioned that as 
yet the presence of CA IV in the carotid bodies has not been demonstrated. 
 
Because AOX reversed the acetazolamide-induced depression of the AHR, scenario 1 could 
involve a role for CA as a ROS scavenger in hypoxia, which then could contribute to (i.e., 
increase) the magnitude of the ventilatory response. However, this remains a matter of 
speculation since experimental evidence is lacking. Also, note that it is unsettled if hypoxia is 
associated with either an increase or decrease in [ROS] and that ROS do not seem to be 
directly involved in oxygen sensing,7 and our results do not shed more light on this. It is 
interesting to note that AOX are also able to reverse cutaneous photosensitivity by 
acetazolamide and other sulfonamide-derived diuretics and antidiabetics,31,32 and that AOX 
such as vitamin E may affect CA activity.33  
 
Scenario 2. Acetazolamide causes intracellular alkalosis in type I carotid body cells, which 
results in a decrease in carotid body output and sensitivity. AOX’s reverse this by an 
independent effect on potassium channels. Acetazolamide causes alkalosis in type I carotid 
body cells from neonatal rat34 and in guinea pig mesenteric smooth muscle cells, it induces 
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alkalosis followed by hyperpolarization, opening of maxi-K (BK) channels and a decreased 
Ca2+ influx.35 Apart from TASK-1 channels,36 maxi-K channels have been shown to play a 
role in oxygen sensing by type I cells from rat carotid body (note that in rabbit and mouse 
Kv channels have been shown to be involved).37-40 A reversal by AOX of the inhibitory effects 
of acetazolamide on the hypoxic response could be explained by the known redox sensitivity 
of potassium channels.5,6 In rabbit type I glomus cells, reducing agents decrease the open 
probability of potassium channels.2 
 
In rat muscle cells, acetazolamide has a BK channel-opening effect which may be mediated 
by a direct action and is not shared by the more lipophilic carbonic anhydrase inhibitor 
methazolamide.15 In cats, 4 mg.kg-1 acetazolamide has a similar inhibitory effect on the 
hypoxic response as we report here in humans.14 Recently, we have compared the effect of 
low-dose acetazolamide and methazolamide on the hypoxic response in this species and the 
surprising finding was that even high-dose methazolamide did not affect it (unpublished 
observations). This suggests that at least in the cat, but possibly also in humans the inhibition 
of the hypoxic response by acetazolamide is not related to inhibition of carbonic anhydrase 
(thereby making the above scenario 1 less likely) but rather to some other pharmacological 
effect of the agent. It remains a matter of speculation whether the inhibiting effect of 
acetazolamide on the hypoxic response may be mediated via a specific effect on one or more 
potassium channels, or, alternatively, to a possible action on various types of L-type calcium 




Because at this stage the possible clinical implications of our observations are a matter of 
speculation we only briefly address two issues, the first of which concerns a possible effect of 
AOX on the hypoxic response per se. Because in previous studies10,11 we were unable to 
demonstrate an effect of AOX on normoxic ventilation and the AHR, we decided not to 
include a separate protocol with AOX alone. Putting our present and previous findings 
together, it seems that in resting conditions, in the absence of inhibiting factors, AOX may not 
alter carotid body output but may increase it when such factors are present. This could be 
important in elderly people (> 70 years): they have been reported to possess a considerably 
lower O2 sensitivity than healthy young adults,43,44 while in women 60–80 years of age 
ascorbic acid supplementation appeared to increase their hypoxic response.9 The ability of 
antioxidants to alter the hypoxic response may vary between different reducing agents. For 
example, Hildebrandt et al. showed that after a 5-day oral application, N-acetylcysteine 
increased the hypoxic response in young adults indicating a possible specific involvement of 
glutathione in oxygen sensing.8 
 
A second issue concerns the possibility that AOX may also alter physiological effects of 
acetazolamide other than the depression of the hypoxic response. For example, the agent has 
well-known beneficial effects in the prevention and treatment of acute mountain sickness 
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(AMS).45 Ascent to high altitude is associated with increased production of ROS that may 
have both advantageous and adverse roles in the adaptation to low environmental PO2.46 
Acetazolamide may prevent or ameliorate symptoms of AMS by an acidosis-induced rise in 
ventilation and/or by reducing pulmonary vasoconstriction, an oxygen-sensitive process that, 
similar to O2 sensing in the carotid bodies, involves potassium channels.47 It remains to be 
seen whether supplemental antioxidants at altitude might interfere with the beneficial effect of 
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6 Effects of Low-Dose Methazolamide on the Control of 
Breathing in Cats 
 
 
Inhibitors of carbonic anhydrase (CA) have complex effects on respiration. Many cells and 
tissues that are involved in the control of breathing contain various isoforms of CA, e.g., red 
cells, carotid bodies, lung and brain capillary endothelial cells, muscle and neurons closely 
associated with central chemoreceptors.1-9 In human and cats, low intravenous doses of 
acetazolamide have both stimulatory and inhibitory effects on the control of breathing.10,11 
One of the inhibitory effects applies to the peripheral chemoreceptors because acetazolamide 
has been shown to reduce the hypoxic response and also the O2–CO2 interaction that is known 
to reside in the carotid bodies.10,12,13 The mechanism by which this occurs is unclear: 
however, due to its physical-chemical properties acetazolamide does not easily cross 
biological membranes,1,2 so that at low dose this inhibiting effect is unlikely due to inhibition 
of an intracellular isoform of CA in the carotid bodies. Methazolamide, another CA inhibitor 
with an about equal affinity for sulfonamide-sensitive CA isoforms, is much more lipophilic 
and rapidly permeates into cells.1,2 Therefore, this agent would be a suitable tool to study the 
effect of intracellular CA inhibition on carotid body-mediated responses. Another difference 
between acetazolamide and methazolamide refers to their effects on large-conductance 
Ca2+-dependent potassium (BK) channels: while acetazolamide specifically opens these 
channels, methazolamide is without any stimulating effect on them.14 Because BK channels 
may play a crucial role in the hypoxic response of type I carotid body cells,5 it is therefore 
interesting to compare the effects of both agents on the carotid body responses to both 
hypoxia and hypercapnia.  
 
Dynamic end-tidal CO2 forcing (DEF) is a suitable means to study the separate effects of 
pharmacological agents on the CO2 sensitivity of the peripheral and central chemoreflex 
loops.16 In this study we have applied this technique to study the effects of low-dose 





Experiments were performed in nine female adult cats (weight 2.5–4.1 kg). The Ethical 
Committee for Animal Experiments of the University of Leiden approved the use of animals. 
The animals were sedated with 10 mg.kg-1 ketamine hydrochloride i.m. Anesthesia was 
induced with 2% sevoflurane in 30% O2 in N2. Both femoral arteries and the right femoral 
vein were cannulated, 20 mg.kg-1 α-chloralose and 100 mg.kg-1 urethane were slowly 
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administered intravenously, and the volatile anesthetic was gradually withdrawn. About 1 h 
later, an infusion of an α-chloralose-urethane solution was started at a rate of                      
1.0–1.5 mg.kg-1.h-1 α-chloralose and 5.0–7.5 mg.kg-1.h-1 urethane.  
 
Respiration 
The trachea was cannulated at midcervical level and connected to a respiratory circuit. Tidal 
volume was measured electronically by integrating airway gas flow obtained from a 
pneumotachograph (number 0 flow transducer, Fleisch, Lausanne, Switzerland) connected to 
a differential pressure transducer (PM 197, Statham, Los Angeles, CA, USA). The respiratory 
fractions of O2 and CO2 were continuously measured with a gas monitor (Multicap, Datex, 
Helsinki, Finland), which was calibrated with gas mixtures of known composition. The 
inspiratory gas concentrations were made with computer-steered mass flow controllers 
(AFC 260, Bronkhorst High-tech BV, Veenendaal, The Netherlands). The end-tidal PCO2 
(PETCO2) and end-tidal PO2 (PETO2) were controlled independently by a PC by adjusting the 
inspiratory gas fractions. Arterial blood pressure was measured using a pressure transducer 
(P23ac, Statham). Arterial blood samples were taken for blood gas analysis (ABL 700, 
Radiometer Copenhagen, Brønshøj, Denmark). 
 
Experimental Design 
Using the DEF technique, we performed step changes in PETCO2 before and after intravenous 
infusion of 3 mg.kg-1 methazolamide (Sigma, Zwijndrecht, The Netherlands), dissolved in 
0.1 N NaOH and 0.1 N HCl (pH was adjusted to 7.3–7.4). PETO2 was kept constant 
throughout the experiments at a normoxic level of 14 kPa. Both before and after 
methazolamide administration, 2 to 4 DEF runs were performed and the dynamic ventilatory 
responses were analyzed (see below). The PETCO2 pattern during a DEF run was as follows. 
After a 10 to 15 min period of steady-state ventilation at constant PETCO2 (about 0.5 kPa 
above the apneic threshold), the PETCO2 was increased by 1–1.5 kPa in a step-wise fashion 
and kept constant for 7 min. Thereafter, the PETCO2 was returned to its previous value and 
maintained for another 7 min. 
 
Dynamic End-Tidal Forcing 
The steady-state relation of inspiratory ventilation (Vi) to PETCO2 at constant PETO2 can be 
described by: 
 
Vi = (Sp + Sc)(PETCO2 – B) 
 
where Sp and Sc are the carbon dioxide sensitivities of the peripheral and central chemoreflex 
loops, respectively, and B is the apneic threshold or extrapolated PETCO2 at zero Vi. The sum 
of Sp and Sc is the overall carbon dioxide sensitivity. 
 
For the analysis of the dynamic response of ventilation to a step-wise change in PETCO2 we 
used a two-compartment model:16 
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Vp(t) + τp d/dt Vp(t) = Sp (PETCO2[t – Tp] – B) 
 
Vc(t) + τc d/dt Vc(t) = Sc (PETCO2[t – Tc] – B) 
 
where τp and τc are the time constants of the peripheral and central chemoreflex loops, 
respectively, Vp(t) and Vc(t) are the outputs of the peripheral and central chemoreflex loops, 
respectively, PETCO2[t – Tp] is the stimulus to the peripheral chemoreflex loop delayed by the 
peripheral transport delay time (Tp), and PETCO2[t – Tc] is the stimulus to the central 
chemoreflex loop delayed by the central transport delay time (Tc). 
 
To allow the time constant of the ventilatory on transient to be different from that of the off 
transient, τc is written as:  
 
τc = x.τon + (1 – x) τoff 
 
where τon is the time constant of the ventilatory on transient, τoff is the time constant of the off 
transient, and x = 1 when PETCO2 is high, while x = 0 when PETCO2 is low. 
 
In most experiments a small drift in ventilation was present. We therefore included a drift 
term (C·t) in our model. The total ventilatory response Vi(t) is made up of the contributions of 
the central and peripheral chemoreflex loops and C·t: 
 
Vi(t) = Vp(t) + Vc(t) + C·t 
 
The parameters of the model were estimated by fitting the model to the breath-by-breath data 
with a least-squares method. To obtain optimal time delays, a grid search was applied, and all 
combinations of Tp and Tc, with increments of 1 s and with Tp smaller than or equal to Tc, 
were tried until a minimum in the residual sum of squares was obtained. The minimum time 
delay was chosen, arbitrarily, to be 1 s, and τp was constrained to be at least 0.3 s. 
 
Statistical Analysis 
To compare the means of the values obtained from the analysis of the DEF runs in the control 
situation with those obtained after methazolamide infusion, analysis of variance was 
performed on individual data. The level of significance was set at P = 0.05. Results are given 





The dose of 3 mg.kg-1 methazolamide did not cause an appreciable arterial-to-end-tidal   
PCO2 (P(a–ET)CO2) gradient indicating the absence of effective erythrocytic CA inhibition  
(P(a–ET)CO2 differences were -0.14 ± 0.27 kPa in control and 0.18 ± 0.27 kPa after 
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methazolamide, P = 0.11). Altogether 57 DEF runs (32 before and 25 after methazolamide) 
were analyzed and the results are summarized in table 1. 
 
 
Table 1. Effects of methazolamide on respiratory parameters. Values are given as mean of the 
mean per cat ± SD (n = 9). 
 
 Control Methazolamide P 
B (kPa) 3.60 ± 0.72 1.77 ± 1.41 0.00006 
Sc (l.min.kPa-1) 0.68 ± 0.27 0.44 ± 0.22 0.013 
Sp (l.min.kPa-1) 0.08 ± 0.04 0.06 ± 0.03 0.13 
Base excess (mM) -6.65 ± 1.75 -7.84 ± 1.90 0.009 
 
 
Methazolamide reduced the apneic threshold and the CO2 sensitivity of the central 
chemoreflex loop. The CO2 sensitivity of the peripheral chemoreflex loop was not 
significantly reduced. The individual data are shown in figure 1. Time constants, delays and 





Our data show a clear decrease in apneic threshold and central CO2 sensitivity by low-dose 
methazolamide. However, we could not demonstrate a significant decrease in peripheral CO2 
sensitivity in our animals. The agent caused a small but significant decrease in base excess. 
 
Previously, we have attributed the decrease in apneic threshold by low-dose acetazolamide to 
a possible effect on the relationship between cerebral blood flow (CBF) and brain tissue PCO2 
(PtCO2).11 Similar to our previous experiments with low-dose acetazolamide, a significant  
P(a–ET)CO2 gradient was also absent after methazolamide, albeit at a somewhat lower dose. 
Methazolamide, however, is a much more permeable inhibitor with an about equal affinity for 
carbonic anhydrase II,1,2 so that compared to acetazolamide (4 mg.kg-1) after 3 mg.kg-1 
methazolamide the fractional inhibition of intracellular CA can be expected to be at least 
equal if not larger. Avoiding complete inhibition is important to prevent large tissue acidosis, 
which then could have explained the large decrease in apneic threshold. Our data show that 
the decrease in mean apneic threshold was considerably larger than after low-dose 
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Figure 1. Scatter diagrams of the respiratory parameters before (control) and after methazolamide. 
 
 
A change in the CBF–PtCO2 relationship may also result in a change in CO2 sensitivity of the 
central chemoreflex loop. Compared to acetazolamide, we now find a smaller decrease in 
central CO2 sensitivity. After low-dose methazolamide, however, inhibition of brain carbonic 
anhydrase could have altered central chemoreceptors CO2 sensitivity for at least two reasons. 
First, carbonic anhydrase has been shown to be present in rostroventrolateral medullary 
structures associated with central chemoreceptors,8,9 and second, in a previous study we 
showed that a high-dose methazolamide caused an increase in CO2 sensitivity independently 
of extracellular and erythrocytic CA inhibition.17 Inhibition of brain carbonic anhydrase is 
followed by decrease in intracellular buffer capacity against CO2.18 Intracellular pH changes 
play a crucial role in central CO2 chemoreception (references see 19). In conclusion, the lower 
decrease in central CO2 sensitivity by methazolamide compared to that by acetazolamide may 
be caused by a combined effect of the former on the CBF–PtCO2 relationship (tending to 
decrease the CO2 sensitivity of the central chemoreflex loop) and on the buffer capacity of 




An interesting finding was that, in contrast to acetazolamide,11 methazolamide did not 
significantly reduce the CO2 sensitivity of the peripheral chemoreflex loop. The carotid 
bodies contain several CA isoforms.4-6,20 Because 3 mg.kg-1 methazolamide will be sufficient 
for complete inhibition of sulfonamide-sensitive carbonic anhydrases within the carotid 
bodies (but not in erythrocytes due to their very large CA content),1,2 its failure to reduce 
peripheral CO2 sensitivity may seem surprising. Causing extracellular rather than extracellular 
and intracellular CA inhibition, low-dose acetazolamide induces a clear reduction in 
peripheral CO2 sensitivity, while the steady-state hypoxic response is reduced by 50%.11,12 
Our findings are reminiscent of data obtained from in vitro carotid body preparations in which 
complete CA inhibition appeared to reduce the fast initial rather than the steady-state CO2 
response.21 One possible explanation of the different effects of methazolamide and 
acetazolamide on the peripheral chemoreflex loop may be related to a specific effect of 
acetazolamide on Ca2+-dependent large-conductance potassium (BK) channels that is not 
shared by methazolamide.14 While acetazolamide has a specific, powerful stimulating effect 
on these channels (i.e., BK channels from skeletal muscles of K+-deficient rat), 
methazolamide entirely lacks such an opening effect.14 As recently shown by Williams 
et al.,15 BK channels may play a crucial role in the response of type I carotid body cells to 
hypoxia. Unpublished data from our lab indicate that in contrast to acetazolamide, low-dose 
methazolamide does not reduce the steady-state hypoxic response in the cat indicating that 
BK channels may indeed be involved in the inhibiting effect of acetazolamide and that CA 
inhibition in the carotid bodies not necessarily reduces their steady-state response to changes 
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7 The Carbonic Anhydrase Inhibitors Methazolamide and 
Acetazolamide Have Different Effects on the Hypoxic 
Ventilatory Response in the Anesthetized Cat 
 
 
Carbonic anhydrase (CA) catalyzes the interconversion of CO2 and bicarbonate and plays a 
crucial role in respiration. To date, fourteen iso-enzymes have been characterized in higher 
vertebrates including humans.1 A specific role of CA in respiration is indicated by the 
presence of various isoforms in tissues and cells that are directly or indirectly involved in 
ventilatory control such as lung and brain capillary endothelium, kidneys, muscles, carotid 
bodies and central chemosensitive areas in the rostroventrolateral medulla oblongata.1,2 
 
Inhibitors of CA have a profound influence on the control of respiration. Due to different 
physical-chemical properties, various sulfonamide CA inhibitors have distinct dose-dependent 
effects. Acetazolamide (AZ), a moderately permeable sulfonamide, is the most frequently 
used inhibitor to study the role of CA in the hypercapnic response of the carotid body and has 
been shown to diminish its steady-state CO2 sensitivity,3,4 although other studies reported only 
a reduced response speed and/or elimination of over- and undershoots in carotid sinus nerve 
activity upon (removal of) sudden hypercapnic stimuli.5,6 AZ reduces the CO2-induced initial 
fast depolarization and nerve activity in type I carotid body cells and co-cultured petrosal 
ganglion neurons, respectively, without changing steady-state responses.7 This is consistent 
with a role of CA in regulating the speed and magnitude of the initial CO2-induced fall in 
intracellular pH in type I cells.8 In a superfused carotid body preparation from cat, AZ reduces 
both the release of dopamine and the increase in carotid sinus nerve discharge upon acidic 
stimuli.9 In the cat, AZ exerts inhibitory effects on carotid body-mediated reflexes. For 
example, low intravenous doses reduce both steady-state hypoxic sensitivity and the O2–CO2 
interaction.10,11 In a dose that completely inhibits erythrocytic CA, it causes a much greater 
rise in ventilation in carotid body denervated than in intact cats,12 while in the latter the 
hypoxic ventilatory response is virtually abolished, an observation that also has been reported 
in man after an intravenous infusion of 500 mg.12-14 To our knowledge, effects of AZ on the 
hypoxic response of the carotid sinus nerve or type I cells have not been reported, but the 
above findings in intact organisms clearly suggest that it may have inhibitory effects.  
 
Methazolamide (MTZ) is a more lipophilic sulfonamide with an about equal KI as AZ for 
CA II and IV.15 MTZ does not seem to affect the magnitudes of the cat carotid sinus nerve 
responses to hypercapnia and hypoxia.5,16,17 Whether MTZ affects the hypoxic response in 
intact organisms is unknown. 
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It would be interesting to compare the effects of AZ and MTZ on the hypoxic ventilatory 
response for two reasons. First, both agents may have different pharmacological effects. 
Recently, Tricarico et al. showed a direct, stimulating, action of AZ on voltage-sensitive 
large-conductance Ca2+-dependent potassium (BK) channels in muscle cells from K+ depleted 
rats,18 an effect that is not shared by MTZ. At least in the rat, BK channels play a role in 
oxygen sensing by the carotid bodies,19-21 but this could not be confirmed in type I cells from 
adult cats.22 Despite the paucity of data on oxygen sensitive potassium channels in type I cells 
from cat, it would be interesting to compare the effects of MTZ and AZ in this species, given 
the different pharmacological properties of these agents. Second, if the elimination of the 
hypoxic response by high-dose AZ is due to inhibition of one or more CA isoenzymes, a high 
dose of the more permeable CA inhibitor MTZ should also abolish it. The purpose of the 
present study in anesthetized cats was to examine if inhibition of carbonic anhydrase in all 
body tissues by an agent other than AZ would reduce or abolish the hypoxic response and, 
second, if AZ could reduce it by a mechanism other than by inhibition of CA isoforms. To 
study the effect of CA inhibition on the hypoxic response, we administered MTZ in a dose 
(33 mg.kg-1) that would inhibit CA in all body tissues. To compare the effects of low doses of 
both sulfonamides, we infused low doses (3 mg.kg-1) of MTZ and AZ (in this order) in a 





Experiments were performed in fifteen adult cats of either sex (mean body weight              
3.55 ± 0.98 kg) after approval by the Ethical Committee for Animal Experiments of the 
University of Leiden. The animals were sedated with 10 mg.kg-1 ketamine hydrochloride i.m. 
Anesthesia was induced with 2% sevoflurane in 30% O2 in N2. Both femoral arteries and the 
right femoral vein were cannulated, 20 mg.kg-1 α-chloralose and 100 mg.kg-1 urethane were 
slowly administered intravenously, and the volatile anesthetic was gradually withdrawn. Then 
an infusion of a α-chloralose-urethane solution was started at a rate of 1.0–1.5 mg.kg-1.h-1 
α-chloralose and 5.0–7.5 mg.kg-1.h-1 urethane to obtain a stable but light anesthesia.23  
 
Respiration 
The trachea was cannulated at midcervical level and connected to a respiratory circuit. Tidal 
volume was measured electronically by integrating airway flow obtained from a 
pneumotachograph (number 0 flow transducer, Fleisch, Lausanne, Switzerland) connected to 
a differential pressure transducer (PM 197, Statham, Los Angeles, CA, USA). The respiratory 
fractions of O2 and CO2 were continuously measured with a gas monitor (Multicap, Datex, 
Helsinki, Finland), which was calibrated with gas mixtures of known composition. The 
inspiratory gas concentrations were made with computer-steered mass flow controllers 
(AFC 260, Bronkhorst High-Tech, Veenendaal, The Netherlands). The end-tidal PCO2 
(PETCO2) and end-tidal PO2 (PETO2) were controlled independently by a PC by adjusting the 
inspiratory gas fractions. Arterial blood samples were taken from the right femoral artery for 
HVR: Acetazolamide versus Methazolamide 
 85
blood gas analysis (ABL 700, Radiometer Copenhagen, Brønshøj, Denmark). Arterial blood 
pressure was measured using a pressure transducer (P23ac, Statham). Rectal temperature was 
maintained within 1 ºC. All signals were converted to digital values (sample frequency 
100 Hz), processed by a PC and stored breath-by-breath. 
 
Study Design 
In a first group of ten animals (group I), we measured the steady-state ventilatory O2 response 
at constant PETCO2 in the control situation. Then, 3 mg.kg
-1 methazolamide (Sigma, 
Zwijndrecht, The Netherlands; dissolved in NaOH, adjusting the pH to about 7.4 with HCl) 
was infused in a volume of about 5 ml (~1 ml.min-1). About 60 min thereafter, a second 
isocapnic steady-state hypoxic response curve was determined. After finishing these 
measurements, 3 mg.kg-1 acetazolamide (Diamox, AHP Pharma, Hoofddorp, The 
Netherlands; 2 mg.ml-1 in saline) was infused and after another 60 min a third steady-state 
isocapnic hypoxic response was measured. 
 
After control measurements in a second group of five animals (group II), an isocapnic 
hypoxic response curve was determined after 3 mg.kg-1 MTZ as described above. Then, to 
obtain complete inhibition of CA in all tissues, these animals were given an additional dose of 
30 mg.kg-1 MTZ, whereafter another isocapnic hypoxic reponse curve was determined. 
 
Isocapnic Hypoxic Response and Data Analysis 
Near step-wise changes in PETO2 were achieved by adjusting the O2 fraction of the inspired 
air; the PETCO2 was kept constant by adjusting the inspired CO2 concentration.24 In this way, a 
new steady-state level of ventilation has established after 5–6 min.24 The last 20 breaths of 
this period were averaged to yield steady-state ventilation at a given PETO2. Blood samples 
were taken at the end of the steady-state periods to analyze blood gases. Using a least square 
method, inspiratory ventilation (Vi) was fitted to arterial PO2 (PaO2) according to the 
exponential function:24,25 
 
Vi = G·exp(–D·PO2) + A 
 
in which G is the overall hypoxic sensitivity (l.min-1), D is a shape parameter (kPa-1 ) and A is 
the ventilation during hyperoxia (l.min-1). None of these three parameters was fixed but all 
were estimated with the aid of an iteration method.  
 
The statistical analysis was performed using SPSS v11.0 for windows (SPSS Inc., Chicago, 
IL, USA). To detect significant differences between the three treatments (control, MTZ and 
AZ), we performed a one-way repeated measures analysis of variance with post-hoc 
Bonferroni correction. P-values < 0.05 were considered significant. Unless otherwise 







In the animals of group I (n = 10), the hypoxic responses were measured by forcing the PETO2 
level from hyperoxia to hypoxia resulting in PaO2 levels that covered the range from         
60.5 ± 4.1 to 5.6 ± 1.4 kPa in control, 57.1 ± 5.7 to 5.7 ± 1.0 kPa after MTZ and 57.6 ± 7.4 to 
5.9 ± 1.2 kPa after AZ.  The dose of 3 mg.kg-1 MTZ did not cause a rise in the mean arterial-
to-end-tidal PCO2 (P(a–ET)CO2) gradient indicating the absence of effective erythrocytic 
carbonic anhydrase inhibition (see table 1). The additional dose of 3 mg.kg-1 AZ caused a 
significant increase in the gradient by about 0.3 kPa, probably too small to cause appreciable 
tissue acidosis and a further rise in hyperoxic ventilation (see table 1). Table 1 also shows that 
MTZ caused a mild acidosis that was more pronounced after the subsequent infusion of AZ. 
 
 
Table 1. Effects of methazolamide (MTZ) and acetazolamide (AZ) on the steady-state hypoxic 
response in ten cats. 
 
 Control MTZ AZ 
G (l.min-1) 1.93 ± 1.32 1.89 ± 0.90 1.09 ± 0.92 * 
D (kPa-1) 0.20 ± 0.07 0.22 ± 0.06 0.14 ± 0.06  
A (l.min-1) 0.86 ± 0.33 1.30 ± 0.40 † 1.32 ± 0.43 ‡ 
PaCO2 (kPa) 4.63 ± 0.75 4.55 ± 0.78 4.78 ± 0.81 
P(a–ET)CO2 (kPa) -0.01 ± 0.30 -0.08 ± 0.38 0.29 ± 0.61 § 
Arterial pH 7.338 ± 0.04 7.307 ± 0.05 § 7.253 ± 0.05 a 
Base excess (mM) -6.75 ± 1.26 -8.56 ± 1.83 b -10.53 ± 1.97 a 
 
* P = 0.003 versus control and P = 0.01 versus MTZ; † P = 0.003 versus control; ‡ P = 0.002 versus 
control; § P = 0.007 versus control; a P = 0.000 versus control; b P = 0.006 versus control   
 
 
An example of the effect of both agents on the hypoxic response in one animal is shown in 
figure 1. The overall results, summarized in table 1, show that the mean control hypoxic 
sensitivity in the ten animals studied was not different from that after MTZ (P = 0.88 versus 
control) while AZ reduced it by 44%.  Compared to the control situation, all animals except 
one had a lower hypoxic sensitivity after AZ administration. The shape parameter D was 
unaffected by MTZ, while AZ tended to reduce it (P = 0.023 versus control). The hyperoxic 
ventilation A increased after MTZ but did not rise further after AZ. 
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Figure 1. Steady-state hypoxic response curves in one animal before (squares) and 
after infusions of, respectively, 3 mg.kg-1 MTZ (open triangles) and 3 mg.kg-1 AZ 
(closed triangles). Curves are optimal fits (least square method) to a 
monoexponential equation with residual. Parameter values for G (l.min-1), D (kPa-1) 
and A (l.min-1) were 1.52, 0.19 and 1.17 in control, 1.1, 0.13 and 1.28 after MTZ and 
0.68, 0.10 and 1.43 after AZ, respectively. 
 
 
The animals of group II (n = 5) were given 3 mg.kg-1 MTZ, followed by 30 mg.kg-1. Hypoxic 
responses in these animals were measured by forcing the PETO2 level from hyperoxia to 
hypoxia resulting in PaO2 levels that covered the range from 58.1 ± 1.1 to 4.9 ± 0.8 kPa in 
control, 54.4 ± 4.3 to 4.9 ± 0.9 kPa after 3 mg.kg-1 MTZ and 56.6 ± 1.5 to 5.0 ± 0.9 kPa after 
30 mg.kg-1 of the agent. In table 2, note the appearance of a large P(a–ET)CO2 gradient after 
33 mg.kg-1, indicating effective inhibition of erythrocytic carbonic anhydrase. An example of 
the effect of low- and high-dose MTZ in one animal is shown in figure 2. The scatter diagram 
of figure 3 shows the individual effect of low-dose MTZ in all fifteen animals (group I and II) 
studied. Note the absence of a systematic increase or decrease of parameter G by MTZ.  All 
five animals of group II showed a substantial response to hypoxia after 33 mg.kg-1 MTZ (in 
three animals parameter G was even larger than in control), which is in sharp contrast after 
high-dose AZ, when the hypoxic response is abolished.12,13 Overall, high-dose MTZ did not 





Table 2. Effects of methazolamide (MTZ) (3 and 33 mg.kg-1, respectively) on the steady-state hypoxic 
response in five cats.  
 
 Control MTZ 3 mg.kg-1 MTZ 33 mg.kg-1 
G (l.min-1) 3.26 ± 1.44 3.23 ± 1.16 3.00 ± 1.23 
D (kPa-1) 0.27 ± 0.07 0.29 ± 0.10 0.27 ± 0.09 
A (l.min-1) 0.79 ± 0.16 0.59 ± 0.21 0.65 ± 0.21 
PaCO2 (kPa) 5.75 ± 0.39 5.76 ± 0.31 6.14 ± 0.21 
P(a–ET)CO2 (kPa) 0.40 ± 0.45 0.66 ± 0.72 2.40 ± 0.54 † 
Arterial pH 7.262 ± 0.03 7.239 ± 0.04  7.217 ± 0.02 * 
Base excess (mM) -7.03 ± 0.88 -8.23 ± 1.27 -8.38 ± 1.09 * 
 
Note that after 33 mg.kg-1 MTZ, the PaCO2, pH and base excess represent equilibrium values in vitro; 
in vivo PaCO2 in the blood perfusing the carotid bodies must have been considerably lower and pH 




                
Figure 2. Example of steady-state response curves in one animal in control 
(squares), 3 mg.kg-1 MTZ (open triangles) and 33 mg.kg-1 MTZ (closed triangles), 
respectively. Curves are optimal fits (least square method) to a monoexponential 
equation with residual. Parameter values for G (l.min-1), D (kPa-1) and A (l.min-1) 
were 3.99, 0.37 and 0.66 in control, 2.31, 0.31 and 0.45 after low-dose MTZ and 
3.70, 0.34 and 0.77 after high-dose MTZ, respectively. 
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Figure 3. Scatter diagram of the effect of 3 mg.kg-1 MTZ on hypoxic sensitivity G in 





The main findings of this sudy can be summarized as follows. First, in a dose (33 mg.kg-1) 
that completely inhibits carbonic anhydrase in all body tissues, methazolamide did not alter 
the steady-state hypoxic ventilatory response in the cat. Second, in a dose of 3 mg.kg-1, the 
less lipophilic sulfonamide acetazolamide reduced hypoxic sensitivity by 44%, while an equal 
low dose of MTZ lacked this effect. These results indicate that full inhibition of CA does not 
reduce the steady-state hypoxic response in the cat and that the depressing effect of AZ may 




Full physiological inhibition of CA is reached when 99.99% of the enzyme is inhibited.26 The 
concentration of CA II in cat erythrocytes is very high providing a possible explanation why 
3 mg.kg-1 MTZ did not widen the P(a–ET)CO2 gradient.27 Because red cells contain much more 
CA than carotid bodies,2 the fractional inhibition of the enzyme after 3 mg.kg-1 MTZ (which 
is evenly distributed) will be larger in the latter. In cat choroid plexus, also an organ with a 
relatively high CA concentration, this dose has shown to result in 99.58% inhibition.28 We 
thus speculate that in the carotid bodies the inhibition will then be close to 99.99% if not 
more, so that a subsequent AZ dose would not exert a physiological effect via inhibition of 
local CA. Although in the absence of concrete data we can not exclude that the additional AZ 
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dose (group I) could have made the difference between incomplete and full carotid body CA 
inhibition, our observation of an entirely intact hypoxic response after a MTZ dose that 
completely inhibits CA in all tissues,2,28 lends support to the view that the inhibiting effect of 
AZ in the animals of group I must be due to an effect unrelated to CA inhibition. Note that the 
AZ dose of 3 mg.kg-1 was somewhat smaller than that was previously shown to reduce the 
hypoxic response.11 
 
Tables 1 and 2 show that 3 mg.kg-1 MTZ caused a decrease in mean pH of 0.031 in group I 
and 0.023 in group II. This mild acidosis could have counteracted an inhibitory effect of the 
agent on the hypoxic response. Low-dose AZ, however, causing a similar degree of mild 
acidosis, clearly reduces hypoxic sensitivity,11,29 indicating that MTZ and AZ have different 
effects on the hypoxic response indeed. In the present study, AZ enlarged the MTZ-induced 
acidosis, but this did not prevent a clear reduction in hypoxic sensitivity. Consequently, AZ 
must have a potent inhibitory effect on the hypoxic response that is not shared by MTZ. 
 
 
Effects of MTZ and AZ on the Hypoxic Ventilatory Response:  Parameters A, D and G 
In both men and animals, the hypoxic response is biphasic, starting with an initial rise in 
ventilation mediated by the carotid bodies, followed by a secondary decrease called hypoxic 
ventilatory depression (HVD). HVD is a poorly understood phenomenon: it is related to the 
magnitude of the initial carotid body stimulation, but possibly also to an increased washout of 
CO2 from brain due to a rise in brain blood flow, and/or a release of inhibitory 
neurotransmitters.30-32  
 
We examined the effects of MTZ and AZ on the steady-state hypoxic response curve, 
described by the exponential function Vi = G·exp(–D·PO2) + A, with hypoxic sensitivity G 
(comprising both the stimulation by the carotid bodies and HVD), shape factor D and 
hyperoxic ventilation A. Neither low- nor high-dose MTZ changed mean hypoxic sensitivity, 
while AZ, given after an equal initial MTZ dose (3 mg.kg-1), reduced it by 44%. The 
hyperoxic ventilation A increased after low- but not high-dose MTZ. AZ tended to reduce 
parameter D. 
 
Parameter A, the ventilation during hyperoxia is a complex variable and is influenced by the 
CO2 sensitivity of the central chemoreflex loop, the X-intercept of the CO2 response curve 
(apneic threshold), the prevailing (arterial and brain stem tissue) PCO2/pH and a small, PCO2-
dependent, contribution of the carotid bodies to total ventilation. Similar to AZ,29 low-dose 
MTZ causes a decrease in sensitivity of the central chemoreflex loop resulting in a less steep 
CO2 response curve (unpublished observations in nine cats) and this would tend to reduce the 
value of parameter A. At the same time, however, also similar to AZ,29 it causes a large 
decrease in the apneic threshold (so CO2 response curves before and after MTZ intersect). The 
influence of the latter effect on parameter A will thus depend on the prevailing PCO2: the 
lower the PCO2 the higher the tendency for low-dose MTZ to increase parameter A. 
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Therefore, because the experiments in the animals of group II were performed at a 
background PCO2 considerably higher than in group I, our finding of an unchanged value of 
A in this group by low-dose MTZ is not necessarily conflicting with the increase in group I. 
 
The physiological significance of the shape parameter D remains unknown and we cannot 
explain the tendency for AZ to decrease it. In our previous study, we did not find an influence 
of AZ on D.11 
 
The most important and surprising findings of this study are that neither low- nor high-dose 
MTZ changed the hypoxic sensitivity G. Previously, we ascribed the elimination of the 
hypoxic response by high-dose AZ solely to a total inhibition of CA isoenzymes in the carotid 
bodies.12,13 Now, however, we may have to reconsider this view because the MTZ dose 
administered in group II (33 mg.kg-1) will inhibit all extracellular membrane-bound CA IV as 
well as intracellular CA I and II.2,26,28 An action of MTZ other than inhibition of CA is not 
known to us, so we can not speculate about a scenario in which complete carotid body CA 
inhibition by MTZ would abolish the O2 response while at the same time an additional 
pharmacological action, not shared by AZ, would reverse this. The alternative, however, an 
action of AZ other than CA inhibition alone that is not shared by MTZ, may open a way to 
discuss our results against a background of recent studies showing unexpected actions of this 
agent. 
 
Although there is evidence indicating that AZ has inhibiting effects on the carotid bodies (see 
introduction), we will discuss possible different effects of MTZ and AZ on both components 
of the hypoxic response namely the initial carotid body-mediated increase in ventilation and 
the secondary decrease (HVD). 
 
 
Different effects of MTZ and AZ on HVD? 
A hypoxia-induced release of inhibitory neurotransmitters may be one of the mechanisms that 
contributes to HVD.30,32 AZ is known to reduce the excitability of neurons that are involved in 
seizures and as such it is used as an anticonvulsant.2,33 Changes in extra- and intracellular pH 
of neurons will influence their excitability, and it is possible that compared to AZ, MTZ, by 
its larger permeability, may have different effects particularly on intracellular pH (pHi) of 
carbonic anhydrase-containing neurons. In hippocampal CA3 neurons, CA inhibitors cause 
intracellular acidosis, and this effect, which is at least partly responsible for their 
anticonvulsant action, is larger with membrane permeant inhibitors.34 Compared to AZ, MTZ 
has a superior inhibiting effect on seizures,2,35 and if this would reflect a general decrease in 
activity in CA-containing neurons, the agent might be expected to promote rather than reduce 
HVD (compared to AZ), assumed that these neurons (or some of them) play a role in it. 
 
Possible different effects of MTZ and AZ on the hypoxia-induced increase in cerebral blood 
flow (CBF) may also result in distinct effects on HVD. AZ has a reputation as a dilator of 
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cerebral vessels, but this effect is clearly dose-dependent and does not seem to be operative 
with intravenous doses lower than 5 mg.kg-1.36 Also, it remains to been seen whether low-dose 
AZ would alter the hypoxia-induced rise in CBF. In humans, after a usual oral clinical dose 
this does not seem to be the case.37 We are not aware of studies showing a dilating effect of 
low-dose MTZ on cerebral vessels. At high dose, CBF will rise by the increase in tissue PCO2 
due to inhibition of erythrocytic CA. 
 
 
Different effects of MTZ and AZ on the Carotid Bodies? 
The most likely explanation for our results is a different effect of MTZ and AZ on the carotid 
bodies. One possibility is that AZ, with its vasodilatory reputation, increases carotid body 
blood flow, while MTZ lacks this effect. Recently, Pickkers et al. ascribed the vasodilatory 
effects of AZ on the peripheral circulation (forearm) in humans to a stimulating effect on 
large-conductance calcium-dependent potassium (BK) channels,38 which they thought might 
be mediated by intracellular alkalosis that they had previously demonstrated in pig mesenteric 
arterial smooth muscle cells.39 Because sulfonamides lacking CA inhibitory effects had a 
much smaller vasorelaxant effect, the authors argued that the inhibition of a CA isoenzyme 
results in intracellular alkalosis, followed by opening of BK channels.38 In an in vitro carotid 
body preparation from cat, the specific BK channel inhibitor charybdotoxin has been reported 
to induce vasodilation indicating that this channel type may be involved in the regulation of 
carotid blood flow in this species.40 For reasons explained above, we believe that if AZ would 
have increased carotid blood flow in our animals, this would most likely be due to an effect 
unrelated to CA inhibition (direct opening of BK channels? –see also below). Unfortunately, 
data on possible effects of MTZ on the peripheral circulation are lacking. From the available 
data in the literature we would certainly expect high-dose AZ to cause a large increase in 
carotid body blood flow. Whether this could explain the elimination of the hypoxic response 
that we showed previously remains to be seen.12,13 Would high-dose MTZ fail to induce 
changes in carotid body blood flow? Studies examining the effects of low- and high-dose 
MTZ on the peripheral circulation and/or carotid body blood flow are warranted. 
 
Finally, we discuss possible different effects of MTZ and AZ on type I carotid body cells.  
Type I cells contain carbonic anhydrase isoenzymes of which the precise subcellular locations 
remain to be elucidated except for the cytosolic isoforms CA II and III (possibly a membrane-
bound isoform is also involved, see references 41–44). There is ample data to indicate that in 
the carotid bodies CA regulates the speed and magnitude of changes in pHi of type I cells 
upon (removal of) sudden hypercapnic stimuli (reference see above). Hypoxia, however, does 
not cause a fall in pHi,45 and in this respect the absence of an effect of MTZ on the hypoxic 
response may not be as surprising as it may seem (also, see references 16 and 17). In this 
context then, we could ascribe the inhibiting effect of AZ to an action that is not related to 
inhibition of CA. The next issue is whether such an effect of AZ, unrelated to CA inhibition, 
could be mediated via BK channels. While there is ample data on the existence of specific 
oxygen-sensitive potassium channels in the carotid bodies of other species, e.g., Kv channels 
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in rabbit and mouse, and TASK-1 and BK channels in rat, the information from cat is 
scarce.20,21,46-48 In one report, it was found that a voltage-sensitive potassium current 
(inhibited by hypoxia) recorded in type I cells from adult cats was insensitive to 
charybdotoxin.22 Another study in an in vitro perfused carotid body reported a decrease in 
carotid sinus nerve activity by this agent during hypoxia.40 Clearly more studies are needed, 
particularly in type I cells from neonatal cat, to identify the oxygen-sensitive potassium 
channels in this species. It would also be interesting to compare the effects of MTZ and AZ in 
rat, because it is now well established that in this species BK channels play a role in oxygen 
sensing by the carotid bodies.21 Finally, because AZ also appears to inhibit (directly or 
indirectly) various types of voltage-sensitive Ca2+ channels,49 we can not exclude that this 
may also have contributed to the difference in effect of MTZ and AZ on the hypoxic 
response. 
 
In conclusion, we have shown different effects of MTZ and AZ on the steady-state hypoxic 
response in the cat that in our opinion are best explained by an action of AZ on carotid body 
blood flow or type I cells that is not related to inhibition of carbonic anhydrase. Our data 
indicate that normal CA activity in the carotid bodies is not a prerequisite for a normal steady-
state hypoxic response to occur. The abolishment of the hypoxic response by high-dose AZ 
that we previously reported is probably mediated by an action other than inhibition of 
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8 Summary and Conclusions 
 
 
The frequent intake and administration of substances for treatment and prevention of disease 
and/or pain has become an inherent part of daily life in the western world. Apart from their 
intended effect, most of these agents (especially those used in anesthetic practice) produce 
side effects. While some side effects are mild and have limited relevance others are 
potentially harmful to the patient. For example, respiratory depression from opioid analgesics 
may cause severe hypoxia, hypercapnia and acidosis and eventually the death of the patient 
(Br J Anaesth 2003; 91: 40-9). It is therefore of clinical importance to study the effects of 
such drugs on the ventilatory control system and understand the underlying mechanisms. This 
may be done by studying the drugs involved (such as opioids) or by studying other agents 
which unearth complex underlying mechanisms and increase our knowledge on ventilatory 
control. Furthermore, in order to avert (that is, prevent or treat) serious complications from 
these drugs it is of imminent importance to develop regimens which reverse drug-affected 
respiratory depression.  
 
The first part of this thesis describes the respiratory effects of the opioid analgesic 
buprenorphine and the ability to reverse buprenorphine-induced respiratory depression with 
the non-specific opioid receptor antagonist naloxone. In the second part of the thesis the focus 
is on the mechanisms of the hypoxic and hypercapnic ventilatory responses. In these studies 
carbonic anhydrase inhibitors are infused in healthy volunteers and anesthetized cats and 
ventilatory responses to isocapnic hypoxia and hypercapnia are measured. Furthermore, the 
interaction of antioxidant treatment and inhibition of the enzyme carbonic anhydrase by 
acetazolamide on the ventilatory response to hypoxia is assessed in healthy volunteers. 
 
In chapter 2, the analgesics buprenorphine and fentanyl were compared with respect to their 
respiratory effects. Data were obtained in humans (healthy volunteers) and awake adult rats. 
Like fentanyl, buprenorphine is a µ-opioid receptor agonist (J Neurosci 2003; 23: 10331-7), 
and causes respiratory depression. For both agents, dose–response relationships were obtained 
(human studies: fentanyl 0–7 µg.kg-1, buprenorphine 0–9 µg.kg-1; these are equianalgesic 
doses). It was observed that buprenorphine displayed a ceiling in respiratory effect: in humans 
respiration declined by about 50% of baseline ventilation at doses > 2 µg.kg-1; in rats, arterial 
PCO2 increased by just 1–1.5 kPa irrespective of dose. In contrast, fentanyl caused a dose-
dependent respiratory effect with periodic breathing and apnea in humans at doses greater 
than 2 µg.kg-1, and a linear dose-dependent increase in arterial PCO2 in rats with death of the 
animals at doses > 90 µg.kg-1. Although these findings suggest that buprenorphine is 
relatively safe (in contrast to fentanyl), one needs to be aware that data were obtained in 
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healthy volunteers (and animals) free of underlying disease, pain and co-medication. How 
buprenorphine behaves in (elderly) patients with pain, co-medication and underlying 
(pulmonary) disease remains unclear and needs further study.  
 
It is clear from the data that buprenorphine performs like a partial agonist over the dose range 
tested with respect to respiratory depression (partial agonism indicates a partial effect despite 
full receptor occupancy). Evidently the data on buprenorphine may be considered clinically 
advantageous only when a similar ceiling effect is not observed for its analgesic 
(antinociceptive) effects. Buprenorphine’s analgesic behavior was examined in chapter 3. In 
humans, the influence of two doses of buprenorphine (0.2 and 0.4 mg per 70 kg) on 
respiration and analgesia was assessed. As expected (chapter 2), buprenorphine’s respiratory 
effects did not differ among the two doses tested. In contrast, a sharp increase in analgesic 
effect was observed going from 0.2 to 0.4 mg buprenorphine. These data (chapters 2 and 3) 
indicate a distinct pharmacological effect of buprenorphine on µ-opioid receptors expressed 
on neurons in the central nervous system involved in analgesia/antinociception (absence of 
ceiling effect, at least over the dose range tested) and µ-opioid receptors expressed on neurons 
involved in respiration (ceiling effect). Although there are various explanations possible for 
this distinct behavior (chapter 3), the most plausible and elegant explanation may be related 
to differences in µ-opioid receptor density in brain areas involved in analgesia/antinociception 
and areas involved in the control of breathing (Pharmaceut Res 2000; 17: 653-9). A relatively 
reduced µ-opioid receptor density in the latter areas may cause the partial agonist 
buprenorphine to display ceiling in respiratory depression, while the abundance of µ-opioid 
receptors in areas involved in analgesia/antinociception may cause the partial agonist 
buprenorphine to behave like a full agonist on analgesia (in contrast, the full µ-opioid agonist 
fentanyl shows an unlimited effect at both end points). 
 
In chapter 4, the ability of naloxone to reverse opioid-induced respiratory depression is 
explored in an extensive set of experiments (data were obtained in 99 subjects). The data 
showed that naloxone reversed morphine- and alfentanil-induced respiratory depression at 
relatively low doses (naloxone doses up to 6 µg.kg-1). In contrast, much greater doses were 
needed to reverse 0.2 and 0.4 mg buprenorphine-induced respiratory depression (doses 
> 30 µg.kg-1). Furthermore, full reversal was only possible when naloxone was given as a 
continuous infusion. The need for the high naloxone dose is related to the high buprenorphine 
µ-opioid receptor affinity (K-values are in the nanomolar range (Eur J Pharmacol 2005; 507: 
87-98)); the need for a continuous infusion to the very short elimination half-life of naloxone. 
Finally, a remarkable and important observation was that naloxone displays a bell-shaped 
dose–response curve (or inverse U-shaped response curve). At doses greater than 5 mg, 
reversal of respiratory depression decreased dose-dependently. These data do remind of the 
bell-shaped dose–response curve which is often observed in animal studies (Br J Pharmacol 
1981; 74: 627-33 (data on analgesia); Br J Pharmacol 1982; 75: 118 (data on respiration); see 
also chapter 1). The best explanation for these findings is the existence of non-competitive 
autoinhibition, in which there are two µ-opioid receptor subpopulations, one mediating the 
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agonistic properties at low dose, the other mediating the antagonistic properties at high dose 
(Life Sci 1981; 29: 2699-708). Irrespective of the mechanism, the data indicate that 
buprenorphine-induced respiratory depression is relatively resistant to reversal by naloxone 
needing a high dose and a continuous infusion. Furthermore, one needs to take into account 
the shape of the naloxone dose–response curve, as too high naloxone doses will be inactive in 
causing reversal of buprenorphine-affected breathing. 
 
The reduction in CO2 sensitivity of the central chemoreflex loop by low-dose methazolamide 
(chapter 6) confirms earlier findings with acetazolamide from the same animal preparation 
(J Physiol Lond 1996; 495: 227-37), and could be explained by assuming a role of carbonic 
anhydrase (CA) in the regulation of cerebral blood flow. The rise in brain blood flow is one of 
the factors that determine the magnitude of the change in brain stem PCO2 –the assumed 
stimulus to the central chemoreceptors– upon (step) changes in end-tidal PCO2. The lower 
central CO2 sensitivity after low-dose acetazolamide and methazolamide might be due to a 
larger brain blood flow response after inhibition of membrane-bound carbonic anhydrase 
(CA IV) in capillary endothelium or at the extracellular face of astrocytes and/or 
oligodendrocytes (J Neurocytol 2000; 29: 263-9; Proc Natl Acad Sci USA 1992; 89: 6823-7; 
Cerebrovasc Dis 2000; 10: 65-9). Acetazolamide is known to cause cerebral vasodilation but 
this effect is dose-dependent and seems to occur only at intravenous doses > 5 mg.kg-1 
(Cerebrovasc Dis 2000; 10: 65-9).  Further studies are warranted to examine the influence of 
low-dose acetazolamide and methazolamide on the steady-state relationship between arterial 
PCO2 and brain blood flow.  
 
From the perspective of enzyme inhibition alone, the reduction in the acute (chapter 5) and 
steady-state (chapter 7) ventilatory sensitivity to hypoxia by low-dose acetazolamide is 
difficult to understand. The carotid body type I cells contain several carbonic anhydrase iso-
enzymes of which CA II and CA III are identified in the rat (J Anat 2003; 202: 573-7), while 
also at least one membrane-bound isoform seems to be present (Neurosci Lett 1994; 166: 
126-30). From animals studies it is clear that inhibition of carbonic anhydrase in the carotid 
bodies by methazolamide slows down its dynamic response upon sudden acidic (hypercapnic) 
stimuli without altering its steady-state sensitivity (Am J Physiol 1991; 265: C565-73). Note 
that, in contrast to low-dose acetazolamide (J Physiol Lond 1996; 495: 227-37), low-dose 
methazolamide did not appear to reduce the CO2 sensitivity of the peripheral chemoreflex 
loop in the cat (chapter 6). A further interesting finding in the in vitro carotid body from cat 
was that methazolamide does not reduce the response to hypoxia. The failure of low-dose 
methazolamide to reduce isocapnic hypoxic sensitivity in the intact cat (chapter 7) may fit 
very well in this scenario. Even more interesting was the finding (chapter 7) that, in sharp 
contrast to acetazolamide (J Appl Physiol 1992; 72: 1717-23), even high-dose methazolamide 
does not reduce hypoxic sensitivity indicating that normal functioning of carbonic anhydrase 




The above findings clearly indicate that acetazolamide and methazolamide have different 
effects on carotid body-mediated responses to changes in PCO2 and PO2. Because on the one 
hand methazolamide, causing full inhibition of carbonic anhydrase in all body tissues, did not 
reduce the hypoxic response, while on the other hand acetazolamide, a less lipophilic inhibitor 
with an even somewhat less affinity to CA II and IV (Mol Pharmacol 1993; 44: 901-5) had 
profound inhibitory effects, suggest that the latter agent may exert its effect by a distinct 
pharmacological action. One interesting possibility is an influence on voltage-sensitive large 
conductance Ca2+-dependent potassium (BK) channels. BK channels belong to the candidates 
of potassium channels that play a role in oxygen sensing by the carotid bodies (Science 2004; 
306: 2093-7). In muscular cells from potassium depleted rats, acetazolamide has shown to 
behave as a specific BK channel opener, while methazolamide entirely lacks this effect 
(FASEB J 2004; 18: 760-1). It is tempting to speculate about the possibility of acetazolamide 
acting via BK channels in the carotid bodies although we have no experimental evidence to 
show this. However, it is of interest to note that the vasorelaxant effect of low-dose 
acetazolamide on the human peripheral circulation has been supposed to be mediated via 
BK channels (Br J Pharmacol 2001; 132: 443-50). Thus low-dose acetazolamide may well 
have measurable physiological effects that are mediated via BK channels. Effects of 
acetazolamide on other channel types such as calcium and sodium channels can also not be 
excluded (chapter 7). 
 
Another interesting feature of potassium channels is their redox sensitivity (Am J Physiol 
1998; 275: C1-24; Clin Exp Pharmacol Physiol 2002; 9: 305-11). Chapter 5 described the 
reduction of the isocapnic ventilatory response to acute (< 5 min) hypoxia and the 
abolishment of the O2–CO2 interaction (i.e., the increase in hypoxic sensitivity with 
increasing PCO2 levels) by acetazolamide and the reversal of these effects by antioxidants in 
humans. The most plausible, although entirely speculative, explanation for these interesting 
observations is that acetazolamide and antioxidants may exert independent and different 
effects on potassium channels (opening by acetazolamide, closure by antioxidants, both 
responses are reported from reduced preparations). The O2–CO2 interaction seems related to 
the intracellular Ca2+ concentration in type I carotid body cells (Am J Physiol 2000; 279: 
L36-42). A hyperpolarizing action of acetazolamide (no matter this is caused by alkalizing the 
cell interior or by directly opening BK channels) could reduce the influx of calcium ions into 
oxygen sensing cells, thus explaining the abolishment of the O2–CO2 interaction by 
acetazolamide that we already had reported previously in the cat (J Physiol 2001; 537: 221-9). 
 
Combining the data from chapter 5 with those of previous studies which showed a reversal 
by antioxidants of carotid body inhibition by subanesthetic concentrations of halogenated 
volatile anesthetics (J Physiol Lond 2002; 544: 931-8 (data on halothane); Anesthesiology 
2005; 102: 47-53 (data on isoflurane); see also chapter 1), the question arises whether 
antioxidants could be a general, easy and relatively harmless tool to relieve the carotid bodies 
from pharmacological inhibition and whether such property of antioxidants could be of 
clinical significance in anesthetic care. More specifically, would antioxidants also be able to 
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reverse depressant effects from opioids (e.g., buprenorphine) more easily than naloxone and 
without affecting their analgesic effect? Another, as yet unexplored, issue is whether 
(membrane permeable) antioxidants would also be able to reverse depressant effects of 
pharmacological agents on central chemoreceptors and respiratory neurons. Both issues will 
be subject of future investigations in our laboratories.  
 
 
In conclusion, at the end it is now possible to address the aims of this thesis as outlined on 
page 15:  
 
1. Description of the dose–respiratory response relationship of buprenorphine and 
fentanyl. The opioid analgesic buprenorphine displays a dose-dependent depression of 
ventilation which levels off at a relatively low dose of 2 µg.kg-1. This phenomenon is well 
described by the term ceiling. In this respect, buprenorphine behaves very differently from 
fentanyl which shows a dose-dependent respiratory effect causing cyclic breathing and 
apnea at doses greater than 2 µg.kg-1. These data indicate that buprenorphine is a partial 
agonist of the µ-opioid receptor. 
 
2. Comparison of the respiratory and analgesic behavior of buprenorphine. In contrast 
to its respiratory behavior (ceiling), buprenorphine’s analgesic behavior is different. Over 
the dose range tested (0 to 6 µg.kg-1) no ceiling is observed. A possible mechanism may 
be found in differences in µ-opioid receptor density in brain areas involved in pain and 
respiration with a reduced density of opioid receptors in areas involved in the control of 
breathing.  
 
3. Reversal of opioid-induced respiratory depression with special interest on 
buprenorphine. In contrast to morphine and alfentanil, buprenorphine is relatively 
resistant to reversal by the aspecific opioid antagonist naloxone. High naloxone doses are 
needed at the correct naloxone dose-window (2 to 4 mg per 70 kg, given in 30 min). 
Greater doses of naloxone produce a decrease in reversal activity. The results of these 
5 studies demonstrate that the specific dose and mode of administration of naloxone is 
very important to obtain a full and long-lasting reversal of buprenorphine-induced 
respiratory depression. The data show that even after administration of large boluses of 
naloxone or boluses plus brief infusions, respiratory depression induced by buprenorphine 
recurs and persists for the duration of the study. Additional studies are required to define 
the dose and the mode of administration of naloxone to restore breathing and maintain it 
at an adequate level in the clinical setting, which is complicated by acute and chronic 
pain, high doses of opioids, long-acting opioids, and various sustained release 





4. Ability of antioxidants to reverse acetazolamide-induced depression of the 
ventilatory response to acute hypoxia. In a complex set of experiments in healthy 
volunteers, it is observed that acetazolamide reduces the isocapnic ventilatory response to 
acute hypoxia (< 3 min) as well as the O2–CO2 interaction at the carotid bodies. A mix of 
ascorbic acid and α-tocopherol (vitamin C and E) is able to reverse the acetazolamide-
induced effects at the carotid bodies. It is argued that these observations are due to 
independent effects of acetazolamide and antioxidants on potassium channels of type I 
carotid body cells. The results of this study not only shed important light on the 
mechanism of oxygen sensing at the carotid bodies but also on the mechanism of 
acetazolamide and its beneficial effect in high altitude disease (mountain sickness). 
Further studies are needed to explore this issue and to address the question whether 
similar mechanisms play a role in oxygen sensing at other sites, such as the pulmonary 
vasculature.  
 
5. Effects of the carbonic anhydrase inhibitors acetazolamide and methazolamide on 
ventilatory responses to hypoxia and hypercapnia. In anesthetized cats, low-dose 
methazolamide lacks a depressant effect on peripheral CO2 sensitivity and the ventilatory 
response to steady-state hypoxia. Even at high dose the ventilatory response to steady-
state hypoxia remains unaffected. In contrast, even at low dose, acetazolamide reduces the 
ventilatory response to acute and steady-state hypoxia. These data strongly suggest that 
carbonic anhydrase is not involved in oxygen sensing at the carotid bodies. They further 
indicate that acetazolamide but not methazolamide interacts with a system (such as a 
protein) which plays a crucial role in oxygen sensing and the ventilatory response to 






8 Samenvatting en Conclusies 
 
 
Het gebruik van geneesmiddelen in de behandeling en preventie van ziekte en pijn is niet 
meer weg te denken uit onze samenleving. De meeste geneesmiddelen hebben behalve hun 
beoogd effect ook bijwerkingen (vooral die middelen die door de anesthesioloog worden 
gebruikt). Het merendeel van deze bijwerkingen is mild en heeft geen consequenties voor de 
patiënt. Sommige bijwerkingen daarentegen zijn potentieel bedreigend. Bijvoorbeeld, 
ademdepressie veroorzaakt door opioïden (morfine en aanverwante stoffen) kan aanleiding 
geven tot het ontstaan van hypoxie, hypercapnie en acidose, en kan soms zelfs de dood van de 
patiënt tot gevolg hebben (Br J Anaesth 2003; 91: 40-9). Het is daarom van belang het effect 
van geneesmiddelen op de ademhaling te bestuderen en de onderliggende mechanismen te 
doorgronden. Dit kan men doen door deze geneesmiddelen zelf te onderzoeken (bijvoorbeeld 
opioïden) of door de bestudering van andere agentia die ons inzicht verschaffen in het 
complexe mechanisme van de ademregulatie. Verder is het van evident belang om 
behandelingen te ontwikkelen die toegepast kunnen worden indien zich levensbedreigende 
bijwerkingen en situaties voordoen zoals bijvoorbeeld ademdepressie door opioïden.  
 
Het eerste deel van dit proefschrift beschrijft de ademhalingseffecten van de opioïde 
pijnstiller buprenorfine en de mogelijkheden om buprenorfine-geïnduceerde ademdepressie 
om te keren met behulp van de niet-specifieke opioïd receptor antagonist naloxon. In het 
tweede deel ligt de nadruk op het mechanisme van de reflexmatige ademhalingsreactie op 
hypoxie en hypercapnie. Remmers van het enzym carbo-anhydrase worden toegediend aan 
vrijwilligers en genarcotiseerde katten en de ademhalingsreacties op isocapnische hypoxie en 
hypercapnie worden gemeten. Tenslotte wordt de interactie tussen antioxidanten en de carbo-
anhydrase remmer acetazolamide op de ademhalingsrespons op hypoxie bestudeerd in 
gezonde vrijwilligers. 
 
In hoofdstuk 2 werden de ademhalingseffecten van twee analgetica vergeleken: fentanyl en 
buprenorfine. Experimenten werden uitgevoerd in de mens (gezonde vrijwilligers) en de 
(wakkere) rat. Buprenorfine veroorzaakt zijn effect, net als fentanyl, door activatie van de 
µ-opioïd receptor (J Neurosci 2003; 23: 10331-7) en veroorzaakt (net als fentanyl) 
ademdepressie. De doses die werden getest varieerden in de mens voor fentanyl van 0 tot 
7 µg.kg-1 en voor buprenorfine van 0 tot 9 µg.kg-1 (het betreft equi-analgetische doses). 
Buprenorfine toonde een duidelijk plafond in het ademhalingseffect: in een dosering groter 
dan 2 µg.kg-1 daalde de ademhaling met maximaal 50% in de mens; in de rat steeg de arteriële 
PCO2 met maximaal 1–1,5 kPa onafhankelijk van de dosis. In tegenstelling tot buprenorfine 
veroorzaakte fentanyl een dosisafhankelijk effect op de ademhaling in de mens met cyclisch 
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ademen en apneu (ademhalingsarrest) bij doses groter dan 2 µg.kg-1, en een lineaire 
dosisafhankelijke stijging van de arteriële PCO2 in de rat met de dood tot gevolg hebbend bij 
doses groter dan 90 µg.kg-1. Hoewel deze bevindingen suggereren dat buprenorfine een 
relatief veilig analgeticum is (in tegenstelling tot fentanyl), moet men in ogenschouw nemen 
dat de hier besproken studies zijn uitgevoerd in gezonde vrijwilligers (en dieren) zonder pijn, 
medicatie en onderliggende ziekten. Hoe buprenorfine zich gedraagt in (oudere) patiënten met 
pijn, medicatie en onderliggende (pulmonale) problematiek blijft onduidelijk en verdient 
verdere studie.  
 
Het is duidelijk dat de data aangeven dat buprenorfine zich in het geteste dosisbereik gedraagt 
als een partiële agonist voor de ademdepressie die het teweegbrengt (een partiële agonist 
veroorzaakt een partieel effect ondanks de volledige bezetting van de betrokken receptoren). 
Deze bevindingen zijn echter dan pas klinisch relevant indien zich een soortgelijk 
plafondeffect niet voordoet voor de beoogde pijnstillende effecten van buprenorfine. Om dit 
te onderzoeken werden in hoofdstuk 3 de ademhalingseffecten en pijnstillende effecten van 
twee doses buprenorfine (0,2 en 0,4 mg per 70 kg) vergeleken in de mens. Zoals eerder 
voorspeld (hoofdstuk 2) was er geen verschil in de ademhalingseffecten van deze twee doses 
buprenorfine.  Het pijnstillend effect nam daarentegen significant toe gaande van 0,2 naar 
0,4 mg buprenorfine. De data die zijn verzameld in hoofdstukken 2 en 3 geven aan dat 
buprenorfine zich anders gedraagt voor de effecten die worden veroorzaakt door activatie van 
µ-opioïd receptoren betrokken bij pijnstilling (geen plafondeffect) versus µ-opioïd receptoren 
betrokken bij de ademhaling (wel plafondeffect). Hoewel er voor dit verschijnsel 
verschillende verklaringen mogelijk zijn (hoofdstuk 3), is de meest waarschijnlijke en 
elegante verklaring een mogelijk verschil in receptordichtheid in de hersendelen betrokken bij 
de twee gemeten eindpunten (Pharmaceut Res 2000; 17: 653-9). Een relatief lage dichtheid 
van µ-opioïd receptoren in die hersendelen betrokken bij ademhaling en een relatief hoge 
receptordichtheid in die delen betrokken bij pijnstilling kan verklaren dat de partiële opioïd 
agonist buprenorfine wel een plafondeffect vertoont voor ademhaling maar niet voor 
pijnstilling (terwijl de volle µ-opioïd agonist fentanyl een ongelimiteerd effect voor beide 
eindpunten laat zien).  
 
In hoofdstuk 4 werd onderzocht of de niet-selectieve opioïd antagonist naloxon in staat is de 
ademdepressie door opioïden om te keren. Het betreft een uitgebreide set experimenten in 
99 proefpersonen. De buprenorfine data moeten worden bezien tegen de achtergrond van de 
waarneming dat naloxon al in een relatief lage dosering (< 6 µg.kg-1) in staat is de 
ademdepressie veroorzaakt door morfine en alfentanil volledig om te keren. Veel hogere 
doses naloxon waren nodig om ademdepressie door buprenorfine (0,2 en 0,4 mg) om te keren 
(doses groter dan 30 µg.kg-1). Ook bleek dat volledige omkering dan slechts mogelijk is 
indien naloxon als continue infusie wordt toegediend. De noodzaak van een hoge dosis 
naloxon is gerelateerd aan de hoge affiniteit van buprenorfine voor de µ-opioïd receptor (Eur 
J Pharmacol 2005; 507: 87-98); de noodzaak van een continue infusie aan de korte 
eliminatiehalfwaardetijd van naloxon. Een opmerkelijke bevinding was dat de naloxon dosis–
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responscurve een omgekeerde U-vorm laat zien. Doses groter dan 5 mg veroorzaakten een 
dosis-afhankelijke afname van de omkering van de ademdepressie. Deze data zijn 
vergelijkbaar met de omgekeerde U-vorm van de buprenorfine dosis–responscurven voor 
antinociceptie en ademdepressie in dierexperimentele studies (Br J Pharmacol 1981; 74: 
627-33 (analgesiedata); Br J Pharmacol 1982; 75: 118 (ademhalingsdata); zie ook hoofdstuk 
1). Een mogelijke verklaring van deze resultaten is het optreden van zogenaamde non-
competitieve autoinhibitie. Hierbij is er sprake van twee µ-opioïd receptorpopulaties: één 
populatie die de agonistische effecten van lage doses buprenorfine medieert, en één populatie 
die de antagonistische effecten medieert na toediening van hoge doses buprenorfine (Life Sci 
1981; 29: 2699-2708). Deze data zijn van klinisch belang. Immers, voor omkering van de 
ademdepressie door buprenorfine zijn relatief hoge doses naloxon en een continue infusie 
noodzakelijk, maar een te hoge dosis zal de omkering bemoeilijken of zelfs tegenwerken. 
  
De afname van de koolzuurgevoeligheid van de centrale chemoreceptoren door een lage dosis 
methazolamide (hoofdstuk 6) is een bevestiging van eerdere bevindingen met acetazolamide 
in hetzelfde dierpreparaat (J Physiol 1996; 495: 227-37). Beide resultaten kunnen verklaard 
worden indien men uitgaat van de rol van het enzym carbo-anhydrase (CA) in de regulatie 
van de hersendoorbloeding. Een toename van de hersendoorbloeding is één van de factoren 
die een rol spelen in de verandering in de hersenstam PCO2 (de vermoedelijke stimulus van 
de centrale chemoreceptoren) na een verandering in eind-expiratoire PCO2. De lagere centrale 
koolzuurgevoeligheid na lage doses acetazolamide en methazolamide kan dan verklaard 
worden door een toename van de hersendoorbloedingsgevoeligheid (voor CO2) na remming 
van de membraangebonden CA isovorm IV. Deze isovorm bevindt zich in het endotheel van 
de bloedvaten in het brein en/of aan de extracellulaire membraanzijde van astrocyten en/of 
oligodendrocyten (J Neurocytol 2000; 29: 263-9; Proc Natl Acad Sci USA 1992; 89: 6823-7; 
Cerebrovasc Dis 2000; 10: 65-9). Acetazolamide veroorzaakt cerebrale vasodilatatie maar dit 
effect is dosisafhankelijk en treedt alleen op indien de dosis groter is dan 5 mg.kg-1 
(Cerebrovasc Dis 2000; 10: 65-9). Verder onderzoek is nodig om de invloed van lage doses 
acetazolamide en methazolamide op de relatie tussen de arteriële PCO2 en de 
hersendoorbloeding vast te stellen.  
 
Vanuit het gezichtspunt van een enzymremming alleen is de afname van de acute (hoofdstuk 
5) en subacute of ‘steady-state’ (hoofdstuk 7) hypoxische ventilatoire gevoeligheid door een 
lage dosis acetazolamide moeilijk te begrijpen. De type I cellen van de glomuslichaampjes 
bevatten verschillende carbo-anhydrase iso-enzymen waarvan CA II en CA III zijn 
aangetoond in de rat (J Anat 2003; 202: 573-7), terwijl ook tenminste één membraangebonden 
isovorm aanwezig is (Neurosci Lett 1994; 166: 126-30). Dierexperimentele studies toonden 
aan dat remming van het carbo-anhydrase in de glomuslichaampjes door methazolamide de 
dynamische reactie op plotselinge zure (hypercapnische) stimuli vertraagt terwijl de steady-
state hypoxische ventilatoire gevoeligheid niet verandert (Am J Physiol 1991; 265: C565-73). 
Opmerkelijk is dat, in tegenstelling tot lage doses acetazolamide (J Physiol Lond 1996; 495: 
227-37), een lage dosis methazolamide de koolzuurgevoeligheid van de perifere 
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chemoreceptoren in de kat niet verlaagde (hoofdstuk 6). Een interessante bevinding in het in 
vitro glomuslichaampje van de kat was dat methazolamide de respons op hypoxie niet 
reduceert. Het resultaat dat een lage dosis methazolamide de isocapnische hypoxische 
gevoeligheid in de intacte kat niet remt (hoofdstuk 7) past hierbij. Nog interessanter is de 
bevinding (hoofdstuk 7) dat, in tegenstelling tot acetazolamide (J Appl Physiol 1992; 72: 
1717-23), zelfs een hoge dosis methazolamide geen depressie van deze respons veroorzaakt. 
Dit alles geeft aan dat een normale activiteit van carbo-anhydrase niet noodzakelijk is voor 
een normale hypoxische ventilatoire reactie. 
 
De bovengenoemde bevindingen wijzen erop dat acetazolamide en methazolamide een 
verschillend effect hebben op de door de glomuslichaampjes gemedieerde reacties op 
veranderingen in arteriële PCO2 en PO2. Terwijl methazolamide, in staat om een volledige 
remming van het enzym carbo-anhydrase in alle weefsels te veroorzaken, de hypoxische 
ventilatoire respons niet deprimeerde, veroorzaakte acetazolamide, een minder lipofiele 
CA-remmer met een zelfs geringere affiniteit voor CA II en CA IV (Mol Pharmacol 1993; 44: 
901-5) juist wel depressie van de hypoxische respons. Dit suggereert dat beide middelen hun 
effect sorteren langs verschillende farmacologische wegen. Acetazolamide heeft invloed op 
de spanningsgevoelige Ca2+-afhankelijke kalium (BK) kanalen. BK kanalen behoren tot die 
kaliumkanalen die een rol spelen bij de zuurstofmeting in het glomuslichaampje (Science 
2004; 306: 2093-7). In spiercellen van kalium-gedepleerde ratten blijkt acetazolamide 
BK kanalen te openen terwijl methazolamide dit effect mist (FASEB J 2004; 18: 760-1). Het 
is verleidelijk te speculeren dat acetazolamide op BK kanalen in de glomuslichaampjes werkt 
hoewel er geen direct bewijs voor is. Indirect bewijs wordt gevormd door het feit dat een lage 
dosering acetazolamide een vaatverwijdend effect heeft door een vermoedelijk effect op 
BK kanalen (Br J Pharmacol 2001; 132: 443-50). Een effect van acetazolamide op andere 
ionkanalen (calcium- of natriumkanalen) kan echter ook niet worden uitgesloten 
(hoofdstuk 7). 
 
Een belangrijke eigenschap van kaliumkanalen is hun redoxgevoeligheid (Am J Physiol 1998; 
275: C1-24; Clin Exp Pharmacol Physiol 2002; 9: 305-11). In hoofdstuk 5 werd beschreven 
dat acetazolamide in de mens de isocapnische acute (< 5 min) hypoxische ventilatoire respons 
deprimeert en dat de O2–CO2 interactie (de toename in hypoxische ventilatoire gevoeligheid 
bij een stijgende PCO2) verdwijnt. Tevens werd aangetoond dat een cocktail van 
antioxidanten het effect van acetazolamide omkeert. De meest plausibele maar vooralsnog 
speculatieve verklaring is dat acetazolamide en antioxidanten onafhankelijke en verschillende 
effecten sorteren op kaliumkanalen (opening door acetazolamide, sluiting door 
antioxidanten). De O2–CO2 interactie blijkt te worden veroorzaakt door een toename in de 
intracellulaire Ca2+-concentratie in de type I glomuscellen (Am J Physiol 2000; 279: L36-42). 
Hyperpolarisatie door acetazolamide (ofwel door een intracellulair alkaliserend effect ofwel 
door de opening van BK kanalen) zou de influx van calciumionen in de zuurstofmetende 
cellen verminderen, hetgeen het verdwijnen van de O2–CO2 interactie, zoals al eerder door 
ons in de kat aangetoond (J Physiol 2001; 537: 221-9), verklaard. 
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Als we alle data beschouwen betreffende de omkering van (acetazolamide en 
inhalatieanesthesie geïnduceerde) ademdepressie door de toediening van antioxidanten 
(hoofdstuk 5; J Physiol Lond 2002; 544: 931-8 (halothaandata); Anesthesiology 2005; 102: 
47-53 (isofluraandata); zie ook hoofdstuk 1), dan rijst de vraag of antioxidanten beschouwd 
mogen worden als een algemene, eenvoudige en relatief onschadelijke manier om 
farmacologische inhibitie van de perifere chemoreceptoren (ter plekke van het 
glomuslichaampje) tegen te gaan. Een tweede vraag is dan of antioxidanten een belangrijke 
rol zouden kunnen spelen in de anesthesiologische praktijkvoering. Zouden antioxidanten, 
makkelijker dan naloxon, de ademdepressieve effecten van opioïden (zoals buprenorfine) 
kunnen omkeren, zonder dat de pijnstillende effecten van deze middelen worden beïnvloed? 
En verder nog, zouden (membraandoorgankelijke) antioxidanten ook de deprimerende 
effecten van farmaca op de centrale chemoreceptoren en ademhalingsneuronen kunnen 
opheffen? Deze vragen zijn onderwerp van verder onderzoek in onze laboratoria. 
 
 
Concluderend, aan het einde van dit proefschrift, is het nu mogelijk de doelstellingen 
beschreven op pagina 15 te bespreken: 
 
1. Beschrijving van de dosis–ademhalingsrespons relatie van buprenorfine en fentanyl. 
De pijnstiller buprenorfine vertoont een dosis-afhankelijke ademdepressie dat een plateau 
bereikt bij 2 µg.kg-1. Dit fenomeen wordt ook wel plafondeffect genoemd. Buprenorfine 
gedraagt zich in dit opzicht anders dan fentanyl dat een dosis-afhankelijke ademdepressie 
veroorzaakt met periodiek ademen en apneu’s na toediening van doses groter dan             
2 µg.kg-1. Deze data geven aan dat buprenorfine een partiele agonist is van de µ-opioïd 
receptor. 
 
2. Vergelijking van de pijnstillende- en ademhalingseffecten van buprenorfine. In 
tegenstelling tot de ademdepressie (waarbij er sprake is van een plafondeffect) laat 
buprenorfine geen plateau zien in de pijnstilling (dosisbereik 0 tot 6 µg.kg-1). Een 
mogelijk mechanisme voor dit verschil zou kunnen liggen in een verschil in µ-opioïd 
receptordichtheid in die delen van het brein die betrokken zijn bij de regeling van de 
ademhaling en de pijnstilling, met een relatieve afgenomen µ-opioïd receptordichtheid in 
de gebieden betrokken bij de ademhaling. 
 
3. Omkering van opioïd-geinduceerde ademdepressie met nadruk op buprenorfine. In 
tegenstelling tot morfine en alfentanil is buprenorfine relatief ongevoelig voor omkering 
door de aspecifieke opioïd antagonist naloxon. Hoge doses naloxon zijn nodig om 
volledige omkering te verkrijgen (2 tot 4 mg per 70 kg, gegeven in 30 min). Hogere doses 
veroorzaken daarentegen een afname van de omkering. Deze 5 separate studies tonen aan 
dat de specifieke naloxon dosis als ook de manier van toediening van groot belang is om 
een volledige en langdurige omkering te krijgen van de ademdepressie die buprenorfine 
veroorzaakt. Nadat de toediening van naloxon (als bolus met of zonder kortdurende 
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infusie) wordt gestopt keert de ademdepressie weer snel terug. Verder onderzoek is nodig 
om de specifieke naloxon dosis en toedieningswijze te bepalen die gebruikt kan worden in 
de kliniek. In de patiënt spelen factoren een rol die niet aanwezig zijn in gezonde 
vrijwilligers, zoals bijvoorbeeld acute en chronische pijn en de toediening van hoog 
gedoseerde opioïden en langwerkende opioïden.  
 
4. Vermogen van antioxidanten om acetazolamide-geïnduceerde depressie van de 
ventilatoire respons op acute hypoxie om te keren. In een serie complexe experimenten 
in gezonde vrijwilligers wordt waargenomen dat acetazolamide de isocapnische 
ventilatoire respons op acute hypoxie (< 3 min) als ook de O2–CO2 interactie in de 
glomuslichaampjes deprimeert. Een cocktail van ascorbinezuur en α-tocopherol (vitamine 
C en E) is in staat het door acetazolamide veroorzaakte effect op de ademhaling volledig 
teniet te doen. Het is waarschijnlijk dat hier sprake is van twee onafhankelijke effecten 
van acetazolamide en antioxidanten op kaliumkanalen in de type I cel van het 
glomuslichaampje. De resultaten van deze studie geven ons niet alleen inzicht in het 
mechanisme van de zuurstofmeting in de cel, maar ook in het mechanisme van 
acetazolamide en in het gunstig effect dat dit middel heeft bij hooggebergteziekte. Verdere 
studies zijn nodig om dit nader te bestuderen en om in te gaan op de vraag of dit zelfde 
mechanisme een rol speelt in de zuurstofmeting in andere cellen dan de type I glomuscel 
(bijvoorbeeld in het longvaatbed). 
 
5. Effecten van de carbo-anhydrase remmers acetazolamide en methazolamide op de 
ventilatoire hypoxische en hypercapnische respons. In de genarcotiseerde kat 
deprimeert een lage dosis methazolamide noch de perifere koolzuurgevoeligheid, noch de 
ventilatoire respons op steady-state hypoxie. Zelfs bij hoge dosis blijft de ventilatoire 
respons op steady-state hypoxie onveranderd. In tegenstelling tot methazolamide 
deprimeert een lage dosis acetazolamide wel de ventilatoire respons op acute en steady-
state hypoxie. Deze data suggereren dat carbo-anhydrase geen bepalende rol speelt in het 
mechanisme van zuurstofmeting in de type I glomuscel. Het geeft verder aan dat 
acetazolamide maar niet methazolamide inwerkt op een systeem (bijvoorbeeld een eiwit) 
dat een cruciale rol speelt in de zuurstofmeting en de hypoxische ventilatoire respons. Een 
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